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ABSTRACT 
In superiority “exploratory” Phase II clinical trials, we often compare the efficacy of 
several doses of an experimental product versus a control group (often a placebo). We 
then use the results from the Phase II to design the subsequent confirmatory superiority 
Phase III trial, and we use statistical methods in the Phase III trial to demonstrate that the 
“best” (most efficacious) dose selected from the Phase II study is superior to the control. 
The two phases are usually separate and independent: the Phase III trial does not 
incorporate patient data from Phase II except, again, in designing the Phase III trial. If we 
can combine data from the two phases into one design and use data from both phases to 
assess efficacy of the most efficacious dose of the experimental treatment versus control, 
we can potentially shorten the overall time of clinical development by reducing the 
overall sample size across Phase II and Phase III combined. This kind of design is the so-
called Adaptive Seamless Designs (ASD). 
In this dissertation, we first review two commonly used combination approaches for the 
adaptive seamless designs. These approaches combine the stagewise p-values and apply 
the closed testing procedure to control the familywise error rate at the nominal level. Due 
  vi 
to their complexity in both understanding and implementation, we propose an approach 
that uses a standard statistical test to compare treatments on the endpoint at the final 
analysis; we derive the distribution of the final test statistic and the critical value required 
to maintain Type I error rate at the nominal level Our simulation studies show our 
approach is comparable to the combination approaches in terms of Type I error rate and 
power.  
An extension to Denne’s sample size re-estimation method is applied in order to estimate 
the final Phase III sample size required to maintain desired power, conditioned on Phase 
II results, when using our proposed adaptive seamless design statistical test. Simulation 
results demonstrate that the type I error rate and power are maintained at the desired 
level.  
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Introduction 
 
 
This dissertation first reviewed two commonly used approaches for the adaptive seamless 
designs (ASD). These approaches combined the stagewise p-values and apply the closed 
testing procedure to control the familywise error rate at the nominal level.  A novel 
method using the exact distribution of the final test statistic was then developed. The 
main advantage of this methodology was avoiding the complicated multiple comparisons 
adjustment procedure and the combination procedure. Then simulation studies were 
conducted to evaluate the Operating Characteristics (OP) including Type I Error and 
power among the Traditional Separate Phase II and Phase III Design, ASD with 
Combination Methods and ASD with our proposed method.  
Next, we explored the sample size re-estimation by using conditional power (CP) (Denne, 
2001) within the framework of our proposed method for ASD. The OP were also 
investigated in the simulation studies as well. 
This dissertation was organized as below: In the first chapter, there would be a general 
introduction of Adaptive Design (AD). The introduction of ASD and the literature review 
of the existing approaches were conducted in Chapter 2. In Chapter 3, we proposed our 
approach and compared the performance of our approach with the other approaches via 
simulation studies.  In Chapter 4, we explored the sample size re-estimation within the 
framework of ASD. The OP were also investigated via simulation studies in this chapter. 
An overall conclusion and discussion was given in Chapter 5. 
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Chapter 1. Adaptive Design 
 
 
1.1 Motivation 
 
According to a recent (1995-2007) R&D spend summary from Pharmaceutical Research 
and Manufactures of America (PhRMA) (Figure 1.1), the costs in pharmaceutical 
research and development increased over twice during 10 years. On the other hand, 
during the same period of time, the New Drug Application (NDA) and Biologic License 
Application (BLA) approvals decreased gradually and remained at a low level. The 
increasing investment did not lead to an increasing success rate of NDA approvals.  
 
Figure 1.1 Number of NDA and BLA vs. PhRMA R&D spending 
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The low success rate of pharmaceutical development could be due to the following 
issues: (i) a diminished margin for improvement escalates the level of difficulty in 
proving drug benefits, (ii) genomics and other new science have not yet reached their full 
potential, (iii) mergers and other business arrangements have decreased candidates, (iv) 
targets of chronic diseases are harder to study, (v) failure rates have not improved, (vi) 
rapidly escalating costs and complexity decreases willingness/ability to bring many 
candidates forward into the clinic.(Woodcock,2005 and Chow et al., 2008) 
To make the process of the drug development more efficient and flexible, people have 
focused on adaptive deign which has been in practice since 1970s. At that time, the 
adaptive design was mostly referred to adaptive randomization or sequential designs 
(Wei, 1978). A more formal way to define adaptive design is a design that allows the 
researcher to modify aspects of the study based on the accumulating data without 
compromising the validity and integrity of the trial (Chow et al., 2008). 
To maintain study validity means ensuring consistency of conditions between different 
stages of the study, reducing operational bias as much as possible and providing accurate 
and the most appropriate statistical inference. 
To maintain study integrity means providing convincing results and safeguarding of 
“blinding” with regard to treatment assignment and interim analysis results. 
There are many ways to classify adaptive designs. According to the adaptations applied, 
some commonly considered adaptive design methods can be summarized as  (i) an 
adaptive randomization design, (ii) a group sequential design, (iii) a sample size re-
estimation design, (iv) a drop-the-loser design, (v) an adaptive dose finding (e.g., dose 
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escalation) design, (vi) a biomarker-adaptive design, (vii) an adaptive treatment-
switching design, (viii) a hypothesis-adaptive design, (ix) an adaptive seamless phase 
II/III trial design, and (x) a multiple adaptive design (Chow et al. 2008). Below are brief 
descriptions of some commonly used designs. If not stating explicitly in the descriptions, 
there is no restriction of the phase in which we can apply the adaptive design methods. 
 
 
1.2 Adaptive randomization design 
 
An adaptive randomization design is a design that allows modification of randomization 
schedules based on varied and/or unequal probabilities of treatment assignment in order 
to increase the probability of success (Chow et al., 2008). Commonly applied adaptive 
randomization procedures include treatment-adaptive randomization, covariate-adaptive 
randomization (Chow et al. 2005), , and response-adaptive randomization (Rosenberger 
et al., 2001, Hardwick et al., 2002). It may not be practical for a trial to have relatively 
long treatment duration because randomization depends on the response of the subjects 
already enrolled in the study and thus the overall drug development time will increase 
(Chow et al., 2008).  
 
 
1.3 Group sequential design  
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 Group sequential methods allow statistical tests to be performed on accumulating data 
and possible early stopping of a trial due to safety, futility or overwhelming efficacy 
based on the statistical results at the interim analysis. When repeated significance testing 
occurs on the same data, multiple adjustments have to be made to the hypothesis testing 
procedure to maintain overall type I error rate at the nominal level. The well-known alpha 
spending function approach provided by Lan & DeMets (1987) and other stopping 
boundary functions (e.g., Wang and Tsiatis, 1987; Rosenberger et al., 2001; Jennison and 
Turnbull, 2000, 2005; Chow and Chang, 2006 ) are commonly used to control the overall 
type I error rate in group sequential designs. 
 
 
1.4 Sample size re-estimation design  
 
Sample size estimation in clinical trials requires good knowledge of the parameters (e.g. 
treatment effect and variability). Due to the uncertainty in the planning phase, sample 
size re-estimation designs have been used to re-estimate the sample size based on interim 
data. 
 
 
1.5 Drop-the-losers design 
 
Drop-the-losers designs are statistical designs that allow dropping the inferior treatments 
at the interim analysis. Based on the findings of the interim analysis, additional treatment 
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arms can also be added (Chow et al., 2008). In the first stage (Phase II), experimental 
treatments and a control are included in the trial. At the end of the first stage the inferior 
arms are dropped by some pre-specified criteria and the winner treatment is selected for 
continuation into the second phase (Phase III), along with the control. At the end of 
study, inference focuses on the comparison of the selected treatment with the control 
using both stages’ data.  
 
 
1.6 Adaptive dose finding design  
 
Adaptive dose finding designs provide more accurate determination of the effective dose 
to move forward to phase III studies so that the success rate increases as well as improves 
the efficiency of the product development process. The strategy is to initially include a 
few patients on many doses to determine the dose-response, then to allocate more patients 
to the dose-range of interest, reducing the allocation of patients to ‘non-informative’ 
doses.   
 
 
1.7 Biomarker-adaptive design  
 
 
Usually in Phase III clinical trial, a biomarker-adaptive design is a design that allows 
modifications based on the response of various biomarkers associated with the disease of 
interests. A biomarker-adaptive design can be used in many areas like selecting the right 
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patient population, identifying natural course of disease, early detection of disease and to 
help in developing personalized medicine (Chakravarty A., 2005; Wang et al., 
2007).  However, it should be kept in mind that there is a gap between identifying 
biomarkers associated with clinical outcomes and establishing a predictive model 
between relevant biomarkers and clinical outcomes in clinical development (Chang, 
2007).   
 
 
1.8 Adaptive seamless phase II/III design 
 
Adaptive seamless phase II/III designs allow a number of most promising experimental 
treatments selected based on the accumulating data from the first stage to continue along 
with the control treatment to the second and any subsequent stages. At the final analysis, 
the data from patients enrolled before and after adaptations will be combined and the 
statistical inference will be made based on the combined data. The development of 
appropriate and valid statistical methods and the control of the overall type I error under 
the complexity of this less well-understood design are major challenges/obstacles to 
clinical scientists (Chow et al., 2011). 
 
In summary, adaptive designs provide flexibility in the clinical development but we need 
to use them with caution due to their complexity. Appropriate statistical methods must be 
established to maintain the validity and integrity of the trial and control the overall Type I 
Error. 
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Chapter 2. Adaptive Seamless Design (ASD) 
 
 
2.1 Background 
 
In superiority “exploratory” Phase II clinical trials, we often compare the efficacy of 
several doses of an experimental product versus a control group (often a placebo).  Then, 
we use the results from Phase II to design the subsequent “confirmatory” superiority 
Phase III trial, and we use statistical methods in the Phase III trial to demonstrate that the 
“best” (most efficacious) dose selected from the Phase II study is superior to the control. 
The two phases are usually separate and independent; the Phase III trial does not 
incorporate patient data from Phase II, except, in designing the Phase III study. Clearly if 
we combine data from the two phases into one design and use data from both phases to 
assess efficacy of the most efficacious dose of the experimental treatment versus control, 
we can potentially shorten the overall time of clinical development and reduce the overall 
sample size by increasing the information value.  
 
 
2.2 Introduction 
 
Figure 2.1 shows the comparison between ASD (top) and the Traditional Phase II and 
Phase III Design (bottom). For a two-stage ASD, several dose levels of the experimental 
product are compared with a placebo. After the first stage (which may also be considered 
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a Phase II trial) of the ASD, multiple testing comparing each dose versus the control is 
conducted to select the “best” dose (e.g., the dose with descriptively the largest beneficial 
effect size versus placebo) is carried forward to the second stage (Phase III) along with 
the placebo.   
For the second stage of ASD, we do not treat patients from the first stage any longer but 
rather recruit and randomize a whole new and independent sample of patients for the 
selected dose and placebo. At the end of the study (second stage, or the Phase III trial), 
we combine the end-of-Phase II data from the Phase II patients who were treated under 
the dose chosen for Phase III with the data from the Phase III patients prior to proceeding 
with the analysis. Both Phases have the same length of follow up. A final comparison is 
performed which makes use of the combined information from both stages. The final 
critical value is adjusted in this final comparison due to the multiple dose comparisons 
and due to the data-driven decision to proceed to Phase III with dose-chosen in Phase II 
so that the overall Type I error is preserved at a pre-specified overall significance level by 
the end of the study. 
Unlike the ASD, there is time lost between the traditional Phase II and Phase III design 
during which data from Phase II is analyzed and Phase III is planned. Furthermore, at the 
end of Phase III, we do not use the data from Phase II for the final analysis. 
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Figure 2.1 Traditional separate Phase II & Phase III design vs. ASD 
 
 
 
2.3 Literature Review 
 
 
Bauer and Kieser (1999) provided a method that applies a combination function (Bauer 
and Köhne, 1994) to combine stage-wise p-values and a closed testing procedure (Marcus 
et al., 1976) to adjust for multiple comparisons in ASD. Section 2.3.1 will introduce two 
commonly used combination functions: Fisher’s combination function (Bauer and Köhne, 
1994) and the weighted inverse normal combination function (Lehmacher and Wassmer, 
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1999). In Section 2.4 we will review some conventional multiple comparisons correction 
methods. In Section 2.5, we will discuss how the combination methods can be performed 
in ASD.  
 
 
2.3.1 Fisher’s combination function 
 
Fisher (1925) proposed a method to combine the results of several independent tests for 
testing a common null hypothesis. Suppose 𝑝1 ⋯ 𝑝𝑘  are p-values of k independent tests 
for testing the same hypothesis H0, then Fisher’s combination function is given by 
𝐶𝐹𝑖𝑠ℎ𝑒𝑟 = −2 ∑ 𝑙𝑛(𝑝𝑖)~χ2k
2𝑘
𝑖=1 . By probability theory, under the null hypothesis H0, the 
individual p-value pi follows a uniform distribution on [0,1]and −𝑙𝑛(𝑝𝑖) follows an 
exponential distribution. It can be proved that multiplying a random variable following an 
exponential distribution by two yields a chi-square distribution with two degrees of 
freedom and the sum of k independent random variables, each following chi-square 
distribution with two degrees of freedom, will yield a chi-square distribution with 2k 
degrees of freedom. Therefore, under the null hypothesis, the statistic 
−2 ∑ 𝑙𝑛(𝑝𝑖) 
𝑘
𝑖=1 follows a chi-square distribution with 2k degrees of freedom.  
When the individual p-values are small then the test statistic will be large, indicating the 
null hypothesis should be rejected. 
Example 2.1, let 𝑝1 = 0.03 𝑎𝑛𝑑 𝑝2 = 0.04 be p-values of two independent tests for a 
common null hypothesis, then, for an one-sided significance level 0.025 test, by the 
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definition of Fisher’s combination function we have −2 ∑ ln(pi) = 13.45 > 11.14 =
𝑘
𝑖=1
χ4,0.25
2 . Therefore, we can reject the null hypothesis. 
 
 
2.3.2 Inverse Normal combination function 
 
Like Fisher’s combination function, the Inverse Normal combination function is another 
widely used method to combine the results of the tests for testing the same null 
hypothesis.  Again suppose 𝑝1 𝑎𝑛𝑑 𝑝2 are p-values of two tests for testing the same 
hypothesis H0, then the test statistic of the Inverse Normal combination function is given 
by (Lehmacher and Wassmer, 1999; Mosteller and Bush, 1954; also Bauer and Köhne, 
1994 and Cui, Hung and Wang, 1999) 𝐶𝐼𝑉𝑁(𝑝1, 𝑝2) = 𝑤1𝛷
−1(1 − 𝑝1) + 𝑤2𝛷
−1(1 −
𝑝2), where Φ is the cumulative density function of the standard Normal distribution and 
𝑤𝑖(𝑖 = 1,2) are pre-specified weights with 𝑤1
2 + 𝑤2
2 = 1  and 0 < 𝑤1, 𝑤2 < 1. If 
𝐶𝐼𝑉𝑁(𝑝1, 𝑝2) > 𝑍1−𝛼 then the one sided size 𝛼 test can be rejected. A common choice of 
the weights is the square root of the proportion of sample size,  𝑖. 𝑒. , 𝑤𝑖 = √
𝑛𝑖
𝑛
, 𝑖 = 1,2  
𝑤ℎ𝑒𝑟𝑒 𝑛𝑖𝑖𝑠 𝑡ℎ𝑒 𝑔𝑟𝑜𝑢𝑝 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒 𝑓𝑜𝑟 𝑠𝑡𝑎𝑔𝑒 𝑖 𝑎𝑛𝑑 𝑛 = 𝑛1 + 𝑛2. When only one dose 
is compared with placebo, then the inverse normal method with these weights is 
equivalent to the classical group sequential design.  
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2.4 Multiple comparisons 
 
The multiple comparisons, multiplicity or multiple testing problem arises when 
considering a set of statistical inferences simultaneously (Miller, 1981). We will start the 
discussion by a simple example. 
Example 2.2, suppose we want to test an experimental drug in a number of medical 
centers. We further define this experimental drug is efficacious over placebo if it shows 
significant results in any one of the multiple medical centers. It is easy to show that the 
more medical centers where we test the drug, the more chances we can detect a 
significant result for the experimental drug. 
The above example shows that as the number of comparisons increases, it becomes more 
likely that a difference between the objects that are compared will be detected.  
In the next sections, we discuss the details of how the multiple comparisons problem 
occurs and commonly used methods to adjust for multiple comparisons. 
 
 
2.4.1 Source of multiple comparisons problem 
 
To understand how the multiple comparisons problem arises, we firstly investigate what 
possible decisions we may make when testing an hypothesis.  
Table 3.1 below shows the classification of all possible decisions of testing a hypothesis. 
There are two errors associated with the decisions we make: the Type I error rate 𝛼 and 
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the Type II error rate 𝛽. Specifically, the Type I error rate 𝛼 is the probability of rejecting 
the null hypothesis H0 or when H0 is true or called false positive rate (falsely rejecting 
H0) and the Type II error rate 𝛽 is the probability of  failing to reject the null hypothesis 
H0 when the alternative hypothesis Ha is true.  The probability of correctly rejecting the 
null hypothesis H0 when the alternative hypothesis Ha is true equals 1 − 𝛽 and is called 
power. 
 
Table 2.1 Type I error and Type II error 
 The Truth 
Decision Null Hypothesis H0 is true Alternative Hypothesis Ha is true 
Fail to Reject 
H0 
Correct Decision 
1  
Wrong Decision 
Type II error   
Reject H0 Wrong Decision 
Type I error   
Correct Decision 
Power 1  
  
After making the classifications of the decisions of testing a hypothesis, next, we show 
that multiple comparisons will increase the Type I Error Rate. More specifically, we 
show that the probability of falsely rejecting at least one null hypothesis is greater 
than significance level𝛼. 
Suppose we want to perform m (𝑚 ≥ 1) hypothesis tests at a time. And let the 
significance level for each test be 𝛼0 = 𝛼. So, 
𝛼0 = 𝑃𝑟𝑜𝑏(𝑓𝑎𝑙𝑠𝑒𝑙𝑦 𝑟𝑒𝑗𝑒𝑐𝑡𝑖𝑛𝑔 𝑡ℎ𝑒 𝑛𝑢𝑙𝑙 ℎ𝑦𝑝𝑜𝑡ℎ𝑒𝑠𝑖𝑠 𝑖𝑛 𝑜𝑛𝑒 𝑡𝑒𝑠𝑡) = 𝛼 
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𝑃𝑟𝑜𝑏(𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑙𝑦 𝑟𝑒𝑗𝑒𝑐𝑡𝑖𝑛𝑔 𝑡ℎ𝑒 𝑛𝑢𝑙𝑙 ℎ𝑦𝑝𝑜𝑡ℎ𝑒𝑠𝑖𝑠 𝑖𝑛 𝑜𝑛𝑒 𝑡𝑒𝑠𝑡) = 1 − 𝛼 
Assume the m tests are independent, then  
𝑃𝑟𝑜𝑏(𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑙𝑦 𝑟𝑒𝑗𝑒𝑐𝑡𝑖𝑛𝑔 𝑎𝑙𝑙 𝑛𝑢𝑙𝑙 ℎ𝑦𝑝𝑜𝑡ℎ𝑒𝑠𝑒𝑠 𝑖𝑛 𝑚 𝑡𝑒𝑠𝑡𝑠) = (1 − 𝛼)𝑚 
𝑃𝑟𝑜𝑏(𝑓𝑎𝑙𝑠𝑒𝑙𝑦 𝑟𝑒𝑗𝑒𝑐𝑡𝑖𝑛𝑔 𝑎𝑡 𝑙𝑒𝑎𝑠𝑡 𝑜𝑛𝑒 𝑛𝑢𝑙𝑙 ℎ𝑦𝑝𝑜𝑡ℎ𝑒𝑠𝑖𝑠 𝑖𝑛 𝑚 𝑡𝑒𝑠𝑡𝑠) = 1 − (1 − 𝛼)𝑚   
Since 0 < 𝛼 < 1, then 0 < 1 − 𝛼 < 1. So (1 − 𝛼)𝑚 becomes smaller as m increases. 
Therefore [1 − (1 − 𝛼)𝑚] − 𝛼 = (1 − 𝛼) − (1 − 𝛼)𝑚 ≥ 0, the equation achieves when 
m=1. Hence 1 − (1 − 𝛼)𝑚 > 𝛼 or in other words, multiple comparisons will inflate the 
Familywise Error Rate (FWER) which is defined as the probability of making at least one 
Type I error when performing multiple comparisons.  
Figure 2.2 and Table 2.2 below show that FWER increases as the number of comparisons 
m increases. In other words, the more comparisons we perform the bigger chance we 
make one or more Type I errors. If no adjustments for multiple comparisons are 
performed, the FWER will increase dramatically. From the table 2.2, we can see that 
when there are 5 comparisons performed the FWER will increase to 0.23 which is 
substantially larger than the 0.05 significance level. Therefore, adjustment procedures 
must be applied to control the FWER at the nominal level for multiple comparisons. In 
the next sections, there will be a brief review of some conventional methods to adjust for 
multiple comparisons.   
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Figure 2.2 Familywise Error Rate vs. The number of comparisons 
 
 
Table 2.2 Familywise error rate vs. number of comparisons 
# of comparisons 1 2 3 4 5 6 7 8 
FWER 0.05 0.098 0.14 0.19 0.23 0.26 0.30 0.34 
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2.4.2 Methods to adjust for multiple comparisons 
 
First let 𝐻1, ⋯ ⋯ , 𝐻𝑚  be a family of hypotheses and 𝑝1, ⋯ ⋯ , 𝑝𝑚 be the corresponding p-
values. Let 𝑇 be the set of true null hypotheses and there are 𝑡 hypotheses in 𝑇. Obviously 
𝑡 ≤ 𝑚. Below we describe several multiple testing procedures commonly used to control 
Type I Error. These can be implemented in both Phase II and Phase III trials. 
 
 
2.4.2.1 Bonferroni Procedure 
 
The Bonferroni Procedure must be the first method mentioned here because it is the most 
trusted, easiest to implement and most conservative approach.  
The Bonferroni Procedure states that if any individual p-value 𝑝𝑖(𝑖 = 1, ⋯ , 𝑚) for the 
elementary hypothesis 𝐻𝑖 is less than or equal to the adjusted significance level, 𝛼𝐵 =
𝛼/𝑚 , then 𝐻𝑖 can be rejected and the FWER can be controlled at 𝛼. The proof of 
controlling FWER at 𝛼 is straightforward by using Boole’s inequality: 
𝐹𝑊𝐸𝑅 = 𝑃𝑟 {⋃ (𝑝𝑖 ≤
𝛼
𝑚
)𝑇 } ≤ ∑ {𝑃𝑟 (𝑝𝑖 ≤
𝛼
𝑚
)}𝑇 ≤ 𝑡
𝛼
𝑚
≤ 𝑚
𝛼
𝑚
≤ 𝛼  
Two notes for Bonferroni Procedure: 
 The independence of the tests is not required for Bonferroni Procedure. 
 The more comparisons we perform the more conservative the Bonferroni 
Procedure is. Hence, for multiple comparisons with large m, it is not appropriate 
to use Bonferroni Procedure. 
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Example 2.3, suppose we want to test  𝐻1, 𝐻2 𝑎𝑛𝑑 𝐻3 simultaneously and the 
corresponding p-values are 𝑝1 = 0.02, 𝑝2 = 0.03 𝑎𝑛𝑑 𝑝3 = 0.01. By the Bonferroni 
Procedure the adjusted significance level, 𝛼𝐵 =
0.05
3
= 0.0167. Since 𝑝1 = 0.02 >
0.0167 = 𝛼𝐵 , 𝑝2 = 0.03 > 0.0167 = 𝛼𝐵 𝑎𝑛𝑑 𝑝3 = 0.01 < 0.0167 = 𝛼𝐵, by 
Bonferroni Procedure we can reject the null hypothesis 𝐻3 but fail to reject the null 
hypotheses 𝐻1  𝑎𝑛𝑑 𝐻2 . 
 
 
2.4.2.2 The Šidák procedure 
 
Šidák(1967) proposed another multiple comparisons adjustment approach to control the 
FWER.  Like the Bonferroni Procedure, it is also very simple to implement, but it is still 
very conservative and requires the individual tests to be independent.  
The Šidák Procedure states that if the test statistics are independent from each other and 
any individual p-value 𝑝𝑖(𝑖 = 1, ⋯ , 𝑚) for the elementary hypothesis 𝐻𝑖 is less than or 
equal to the adjusted significance level, 𝛼𝑆 = 1 − (1 − 𝛼)
1
𝑚 , then 𝐻𝑖 can be rejected and 
the FWER can be controlled at 𝛼.  
The proof of Šidák Procedure is straightforward.  Suppose that the significance threshold 
for an individual test is 𝛼0. Since the individual tests are independent, we have shown 
that  
𝑃𝑟𝑜𝑏(𝑓𝑎𝑙𝑠𝑒 𝑟𝑒𝑗𝑒𝑐𝑡𝑖𝑛𝑔 𝑎𝑡 𝑙𝑒𝑎𝑠𝑡 𝑜𝑛𝑒 𝑛𝑢𝑙𝑙 ℎ𝑦𝑝𝑜𝑡ℎ𝑒𝑠𝑖𝑠 𝑖𝑛 𝑚 𝑡𝑒𝑠𝑡𝑠) = 1 − (1 − 𝛼0)
𝑚 
𝐿𝑒𝑡 1 − (1 − 𝛼0)
𝑚 = 𝛼, 𝑡ℎ𝑒𝑛 (1 − 𝛼0)
𝑚 = 1 − 𝛼  
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1 − 𝛼0 = (1 − 𝛼)
1
𝑚 , 𝑠𝑜 𝛼0 = 1 − (1 − 𝛼)
1
𝑚 = 𝛼𝑆  
Example 2.4, again suppose we want to test  𝐻1, 𝐻2 𝑎𝑛𝑑 𝐻3 simultaneously and the 
corresponding p-values are 𝑝1 = 0.02, 𝑝2 = 0.03 𝑎𝑛𝑑 𝑝3 = 0.01. By the Šidák 
Procedure the adjusted significance level, 𝛼𝑆 = 1 − (1 − 0.05)
1
3 = 0.017. Since 𝑝1 =
0.02 > 0.017 = 𝛼𝑆 , 𝑝2 = 0.03 > 0.017 = 𝛼𝑆 𝑎𝑛𝑑 𝑝3 = 0.01 < 0.017 = 𝛼𝑆, by the 
Šidák Procedure we obtain the same results as the Bonferroni Procedure which rejects the 
null hypothesis 𝐻3 but fails to reject the null hypotheses 𝐻1  𝑎𝑛𝑑 𝐻2   
 
 
2.4.2.3 Tukey's procedure 
 
Tukey’s procedure is performed after an analysis of variance (ANOVA) to determine 
which groups in the sample differ. While ANOVA can tell the researcher whether groups 
in the sample differ, it cannot tell the researcher which groups differ. Assuming 
independence of the observations being tested and equal variation across observations, 
the Tukey’s procedure can be applied to make the multiple 2-group comparisons and 
control the FWER at the nominal level. The formula for Tukey's test is: 
𝑞𝑇 =
𝑌𝐴 − 𝑌𝐵
𝑆𝐸
 
where YA is the larger of the two means being compared, YB is the smaller of the two 
means being compared, and SE is the standard error of the data. 
This 𝑞𝑇 value can then be compared to a q value from the studentized range 
  
20 
distribution. If the 𝑞𝑇 is larger than the qcritical value obtained from the distribution, we 
can claim that the two means are significantly different (Linton et al., 2007).  
 
 
2.4.2.4 Holm's step-down procedure  
 
Holm (1979) proposed a simple stepwise procedure to control the FWER of the multiple 
comparisons problem.  It is shown to be uniformly more powerful than the Bonferroni 
Procedure. 
The method algorithm proceeds as follows: 
 Order the p-values from smallest to largest and denote them by   𝑝(1), ⋯ ⋯ , 𝑝(𝑚) 
and let 𝐻(1), ⋯ ⋯ , 𝐻(𝑚) be associated hypotheses. 
 For a test with significance level 𝛼, find the minimum index k such that 𝑝(𝑘) >
𝛼
𝑚+1−𝑘
 
 Reject the null hypotheses 𝐻(1), ⋯ ⋯ , 𝐻(𝑘−1) and do not reject the null hypotheses 
𝐻(𝑘), ⋯ ⋯ , 𝐻(𝑚) 
 If k=1 then none of the hypotheses can be rejected and if no such k can be found 
then reject all hypotheses 
To prove that Holm's step-down procedure controls the FWER at the nominal level, we 
assume we falsely reject at least one true null hypothesis and let k be the first (with 
respect to the order of p-values) rejected true null hypothesis. Because there are at least t-
1 true null hypotheses between k and m, then 𝑚 − 𝑘 ≥ 𝑡 − 1 𝑜𝑟 𝑘 ≤ 𝑚 − 𝑡 + 1. Since 
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𝐻(𝑘) is rejected, by Holm's step-down procedure we have 
𝑝(𝑘) ≤
𝛼
𝑚+1−𝑘
≤
𝛼
𝑚+1−(𝑚−𝑡+1)
=
𝛼
𝑡
. That means if we falsely reject a true null hypothesis 
then its p-value will be less than or equal to  
𝛼
𝑡
. 
Define 𝐴 = {𝑝𝑖 <
𝛼
𝑡
, 𝑓𝑜𝑟 𝑠𝑜𝑚𝑒 𝑖 ∈ 𝑇} be the subset of true null hypotheses that are 
falsely rejected. Then by the Bonferroni Inequality we have 𝑃𝑟(𝐴) ≤ 𝛼 which means the 
Holm’s step-down procedure controls the FWER at 𝛼. 
Example 2.5, again suppose we want to test  𝐻1, 𝐻2 𝑎𝑛𝑑 𝐻3 simultaneously and the 
corresponding p-values are 𝑝1 = 0.02, 𝑝2 = 0.03 𝑎𝑛𝑑 𝑝3 = 0.01. Then the ordered p-
values are 𝑝(1) = 0.01, 𝑝(2) = 0.02 𝑎𝑛𝑑 𝑝(3) = 0.03. First we check the smallest p-value 
𝑝(1). Since 
0.05
3+1−1
= 0.0167 > 0.01 = 𝑝(1), we move to check 𝑝(2) 𝑎𝑛𝑑 𝑝(3) . Similarly, 
0.05
3+1−2
= 0.025 > 0.02 = 𝑝(2) 𝑎𝑛𝑑 
0.05
3+1−3
= 0.05 > 0.03 = 𝑝(3). Since no such k 
satisfies 𝑝(𝑘) >
𝛼
𝑚+1−𝑘
 , by Holm’s step-down procedure we reject all null hypotheses. 
 
 
2.4.2.5 Hochberg's step-up procedure 
 
Hocheberg (1988) modified Holm’s step-down procedure and proposed a step-up 
algorithm to control the FWER. Though Hochberg’s Procedure is more powerful than 
Holm’s Procedure, it holds under the independent assumption because it is based on 
Simes test (1987). 
 The algorithm can proceed as follows: 
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 Order the p-value from smallest to largest and denote them by   𝑝(1), ⋯ ⋯ , 𝑝(𝑚) 
and let 𝐻(1), ⋯ ⋯ , 𝐻(𝑚) be associated hypotheses. 
 For a test with significance level 𝛼, find the maximum index k such that 𝑝(𝑘) ≤
𝛼
𝑚+1−𝑘
 
 Reject the null hypotheses 𝐻(1), ⋯ ⋯ , 𝐻(𝑘) and do not reject the null hypotheses 
𝐻(𝑘+1), ⋯ ⋯ , 𝐻(𝑚) 
 
 
2.4.2.6 Dunnett’s test   
 
The Canadian statistician Charles Dunnett (1955) developed a multiple comparisons 
procedure to compare each treatment group to the control group instead of all pairwise 
comparisons. Since all of the comparisons use the same control group, the test takes the 
correlation between the test statistics into consideration. However, since using this test 
relies on the table of critical values which is not widely available, we always need the 
help of statistical software when performing this test.  
 
   
2.4.2.7 Closed Testing Procedure 
 
The closed testing procedure proceeds as follows.  
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1. Let 𝐻𝑖: 𝜇𝑖 = 𝜇0, 𝑖 ∈ 𝜑 = {1, ⋯ , 𝑙} be the elementary null hypothesis, where 𝜇𝑖  𝑎𝑛𝑑 𝜇0 
are the effect size of dose i and placebo respectively. 
2. For each subset 𝐼of 𝜑, define the intersection hypothesis 𝐻𝐼 = ⋂ 𝐻𝑖𝑖∈𝐼 . 
3. Construct a level 𝛼test for each intersection hypothesis. 
4. The hypothesis 𝐻𝑖 is rejected overall if, and only if, 𝐻𝐼  is rejected at level 𝛼 for every 
set 𝐼 containing 𝑖. 
For step 3, common multiple testing methods can be used to construct the test for the 
intersection hypothesis. For example, suppose 𝑝𝑖is the p-value for 𝐻𝑖, then by Bonferroni 
adjustment, the overall p-value for testing 𝐻𝐼  is 𝑚 ∗ min𝑖∈𝐼 𝑝𝑖, where m is the number of 
indices in 𝐼. Other multiple adjustment methods like Simes’ method or Dunnett’s method 
can be applied as well.  
A strong FWER control can be defined as the FWER is controlled at level 𝛼 for any 
configuration of the true and false null hypotheses. The proof that the closed testing 
procedure strongly controls the FWER is straightforward (Jennison and Turnbull, 2007). 
Let 𝐼  be the set of all true null hypotheses 𝐻𝑖. For a familywise error to be committed, 𝐻𝐼 
must be rejected. Since 𝐻𝐼 is true, by the closed testing procedure 𝑃𝑟{𝑟𝑒𝑗𝑒𝑐𝑡 𝐻𝐼} ≤ 𝛼, 
thus the probability of a familywise error is no greater than 𝛼. 
Example 2.6, suppose we have 3 elementary null hypothesis H1, H2 and H 3 to test and 
their corresponding p-values p1=0.03, p2=0.028 and p3=0.015. Firstly, we consider the 
null hypothesis H1. If no multiple comparisons involved, we can reject the null because 
the pvalue p1=0.03<0.05 for a two sided size 0.05 test. But for this case since we also test 
H2 and H3 at the same time, we need to perform the multiple adjustment to avoid the 
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inflation of type I error. The closed testing procedure says, if we want to reject H1, we 
need to reject all intersection hypotheses containing H1 which are 
𝐻1, 𝐻1 ⋂ 𝐻2 , 𝐻1 ⋂ 𝐻3 , 𝐻1 ⋂ 𝐻2 ⋂ 𝐻3. For simplicity, we use Bonferroni method to 
compute the pvalue for the intersection null hypothesis.  
p-value(𝐻1)=0.03<0.05 
p-value(𝐻1 ⋂ 𝐻2)=2*min(p1, p2)=2*min(0.03,0.028)=2*0.028=0.056>0.05 
p-value(𝐻1 ⋂ 𝐻3)=2*min(p1, p3)=2*min(0.03,0.015)=2*0.015=0.03<0.05 
p-value(𝐻1 ⋂ 𝐻2 ⋂ 𝐻3)=3*min(p1,p2,p3)=3*min(0.03,0.028,0.015)=3*0.015 
=0.045<0.05 
Since we find one p-value for intersection hypothesis 𝐻1 ⋂ 𝐻2=0.056>0.05, by the closed 
testing procedure, we failed to reject the null hypothesis of 𝐻1. 
Similarly, for the elementary null hypothesis H3, the set of intersection hypotheses 
is {𝐻3, 𝐻1 ⋂ 𝐻3 , 𝐻2 ⋂ 𝐻3 , 𝐻1 ⋂ 𝐻2 ⋂ 𝐻3}. Again, apply the Bonferroni method to 
compute the intersection p-values.   
p-value(𝐻3)=0.015<0.05 
p-value(𝐻1 ⋂ 𝐻3)=2*min(p1, p3)=2*min(0.03,0.015)=2*0.015=0.03<0.05 
p-value(𝐻2 ⋂ 𝐻3)=2*min(p2, p3)=2*min(0.28,0.015)=2*0.015=0.03<0.05 
p-value(𝐻1 ⋂ 𝐻2 ⋂ 𝐻3)=3*min(p1,p2,p3)=3*min(0.03,0.028,0.015)=3*0.015 
=0.045<0.05 
Since all intersection hypotheses containing H3 have p-value<0.05, by the closed testing 
procedure, we can reject the null hypothesis H3. 
 
  
25 
2.5 Combination Methods for ASD  
 
By applying the combination functions on the stage-wise p-values and the closed testing 
procedure to strongly control FWER, the design proceeds as the Figure 2.3 shows and we 
summarize it as the following steps: 
Stage 1 (Phase II) 
(1) Suppose we have n groups of experimental doses (𝐷𝑜𝑠𝑒 1 ⋯ 𝐷𝑜𝑠𝑒 𝑛) and a Placebo 
group in stage 1 and at the interim analysis (end of the stage 1), we compute 𝑝1,{𝑖}(p-value 
for Dose 𝑖 vs. Placebo in stage 1)  
(2) We select the “best” dose with the smallest stage 1 p-value (assume it is Dose j) and 
compute corresponding intersection hypotheses p-values by using the pre-specified 
multiple adjustment procedure (e.g., Bonferroni etc.). 
Stage 2 (Phase III) 
(1) For stage 2, we recruit new patients and continue the study with Dose j and placebo, 
resulting in 𝑝2,{𝑗} only based on the stage 2 patients (independent from𝑝1,{𝑗}) 
(2) Combine 𝑝1,{𝑗} and the intersection p-values containing dose j with 𝑝2,{𝑗} using the 
combination functions and decide for or against the null hypothesis of 𝐻0: 𝜇𝑗 = 𝜇0 by 
using the closed testing procedure to adjust for multiple comparisons in stage 1.  
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Figure 2.3 Flow Chart of the Combination Methods for ASD 
 
We will illustrate the Combination Method by using the example below. 
Example 2.7, suppose we have 3 doses (A, B and C) and a placebo and let the 
corresponding elementary null hypotheses be HA, HB and HC. At the interim analysis, we 
obtain p-values for the 3 dose groups: pA,1=0.03, pB,1=0.028 and pC,1=0.015 respectively. 
We select Dose C as the “best” dose to continue since its p-value is the minimum in the 3 
dose groups. For simplicity, we apply the Bonferroni method to compute the intersection 
p-values for Dose C. 
p1=p-value(𝐻𝐶,1)=0.015 
p2=p-value(𝐻𝐴,1 ⋂ 𝐻𝐶,1)=2*min(pA,1, pC,1)=2*min(0.03,0.015)=2*0.015=0.03 
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p3=p-value(𝐻𝐵,1 ⋂ 𝐻𝐶,1)=2*min(pB,1, pC,1)=2*min(0.28,0.015)=2*0.015=0.03 
p4=p-value(𝐻𝐴,1 ⋂ 𝐻𝐵,1 ⋂ 𝐻𝐶,1)=3*min(pA,1,PB,1, pC,1) 
    =3*min(0.03,0.028,0.015)=3*0.015=0.045 
Suppose at the final analysis, we have the p-value for the Dose C only based on the stage 
2 data of pC,2=0.04. Then we apply the Fisher’s Combination Function to combine it with 
the intersection p-values from stage 1.   
−2𝑙𝑛(𝑝1𝑝𝐶,2) = 14.84 > 11.14 = χ4,0.25
2  
−2𝑙𝑛(𝑝2𝑝𝐶,2) = 13.45 > 11.14 = χ4,0.25
2  
−2𝑙𝑛(𝑝3𝑝𝐶,2) = 13.45 > 11.14 = χ4,0.25
2  
−2𝑙𝑛(𝑝4𝑝𝐶,2) = 12.64 > 11.14 = χ4,0.25
2  
 
Since all combined statistics for the intersection hypotheses containing Dose C are larger 
than the critical value, by the closed testing procedure, we can reject the null hypothesis.  
 
 
In this chapter, we introduced two combination functions to combine p-values: Fisher’s 
combination function and inverse normal combination function. Then we reviewed some 
conventional multiple comparisons correction methods. Finally, we discussed the 
procedure of applying combination functions and the closed testing procedure for ASD. 
In the next chapter, we propose a new method for ASD. 
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Chapter 3.  The ASD with our proposed method 
 
 
3.1 Motivation 
 
The ASD with a combination method has some advantages, for example it is compatible 
with inconsistent endpoints of the two stages. But since it relies on the combination 
functions to combine the stagewise p-values and the closed testing procedures to control 
the FWER, it becomes very complicated in both understanding and implementation. 
Instead, we propose a method without involving such sophisticated procedures. In short, 
at the final analysis we calculate the standard Z or t test statistic using the pooled data 
from both stages instead of combining the stagewise p-values and we derive the exact 
distribution of the final critical value to control the Type I Error and ensure adequate 
power.   
 
3.2 Procedure 
The procedure of our proposed method proceeds is:  
Stage 1 (Phase II) 
Suppose we have n groups of experimental doses (𝐷𝑜𝑠𝑒 1 ⋯ 𝐷𝑜𝑠𝑒 𝑛) and a Placebo 
group in stage 1 and at the interim analysis (end of the stage 1), we compute 𝑝1,𝑖 : the p-
value for Dose 𝑖 vs. Placebo in stage 1. We select the “best” dose with the smallest stage 
1 p-value (assume it is Dose 𝑗)  
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Stage 2 (Phase III) 
For stage 2, we recruit new patients and continue the study with Dose 𝑗 and Placebo. At 
the final analysis, we compute the regular Z or t test statistic for the comparison between 
Dose 𝑗 and Placebo based on the combined data from the two stages and an adjusted 
critical value. Finally, we decide for or against the null hypothesis of 𝐻0: 𝜇𝑗 = 𝜇0  
according to whether the final test statistic Z is larger than adjusted critical value(reject) 
or not. In the next section, we discuss how to derive the adjusted critical value for the 
final statistic. 
 
 
3.3 The derivation of the distribution of the final test statistic 
 
 1) We derive the covariance of the test statistics at the interim analysis. For simplicity, 
we assume the variances of each treatment group are equal and all 𝜎2 = 1. Suppose we 
have N doses and a placebo and we assume a 1-1 randomization (i.e. the sample sizes in 
each treatment group are equal, say, n), then the test statistic at the interim analysis for 
dose i can be written as 
 𝑍𝑖 =
?̅?𝑖−?̅?0
√2𝜎
2
𝑛
=
√𝑛(?̅?𝑖−?̅?0)
√2
, 𝑖 = 1, ⋯ , 𝑁 𝑤ℎ𝑒𝑟𝑒 𝑋?̅?𝑖𝑠 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑑𝑜𝑠𝑒 𝑖. Here, we 
assume there is no correlation between the treatments which is the usual circumstance, 
i.e. 𝑐𝑜𝑣(𝑋?̅?, 𝑋?̅?) = 0, 𝑖 ≠ 𝑗. Next we compute the covariance of 𝑍𝑖 𝑎𝑛𝑑 𝑍𝑗, 𝑖 ≠ 𝑗 ≠ 0.  
  
30 
𝐶𝑜𝑣(𝑍𝑖, 𝑍𝑗)   = 𝐶𝑜𝑣 (
√𝑛(?̅?𝑖 − ?̅?0)
√2
,
√𝑛(?̅?𝑗 − ?̅?0)
√2
) = √
𝑛
2
𝐶𝑜𝑣(?̅?𝑖 − ?̅?0 , ?̅?𝑗 − ?̅?0)√
𝑛
2
=
𝑛
2
𝐶𝑜𝑣(?̅?𝑖 − ?̅?0 , ?̅?𝑗 − ?̅?0)
=
𝑛
2
[𝐶𝑜𝑣(?̅?𝑖  , ?̅?𝑗) − 𝐶𝑜𝑣(?̅?0 , ?̅?𝑗) − 𝐶𝑜𝑣(?̅?𝑖 , ?̅?0) + 𝐶𝑜𝑣(?̅?0 , ?̅?0)]
=
𝑛
2
(0 − 0 + 0 + 𝑉𝑎𝑟(?̅?0)) =
𝑛
2
∗
1
𝑛
= 0.5 
Therefore, the test statistics at the interim analysis follow a multivariate normal 
distribution with mean=0, variance=1 and covariance=0.5, ie,  
(
𝑍1
𝑍2
⋮
𝑍𝑁
) ~𝑀𝑉𝑁 ([
0
0
⋮
0
] , [
1 0.5  ⋯ 0.5
0.5
⋮
⋱
⋮
0.5
0.5 0.5  ⋯ 1
])  (3.1) 
Since at the interim analysis, we select the dose with maximum test statistic (minimum p-
value), we need to know the distribution of the maximum of 𝑍1, ⋯ , 𝑍𝑁 that follow the 
distribution (3.1).  
Denoting 𝑍(𝑁) = max (𝑍1, ⋯ , 𝑍𝑁), Gupta(1963) noted that the cumulative distribution 
function (cdf) of the maximum of N correlated Normal standardized random variables is 
 𝐹𝑍(𝑁)(𝑧, 𝜌) = 𝑃𝑟(𝑍(𝑁) < 𝑧) = ∫ 𝛷
𝑁 (
𝑥√𝜌+𝑧
√1−𝜌
) 𝜙(𝑥)𝑑𝑥
∞
−∞
   (3.2), where 𝛷(𝑥) 𝑎𝑛𝑑 𝜙(𝑥) 
are the cdf and probability distribution function (pdf) of standardized normal random 
variable respectively and 𝜌 is the correlation coefficient. 
Since in our case the correlation 𝜌 = 0.5 , we can write the cdf of 𝑍(𝑁) as  
𝐹𝑍(𝑁)(𝑧) = 𝐹𝑍(𝑁)(𝑧, 0.5) = 𝑃𝑟(𝑍(𝑁) < 𝑧) = ∫ 𝛷
𝑁 (
𝑥√0.5 + 𝑧
√0.5
) 𝜙(𝑥)𝑑𝑥
∞
−∞
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Next, we will derive the pdf of 𝑍(𝑁) .  
Theorem 3.1 (Leibniz’s rule), for x in (x0,x1) the derivative of the integral ∫ 𝑓(𝑥, 𝑦)𝑑𝑦
𝑦1
𝑦0
 
is expressible  
𝑑
𝑑𝑥
(∫ 𝑓(𝑥, 𝑦)𝑑𝑦
𝑦1
𝑦0
) = ∫
𝑑
𝑑𝑥
(𝑓(𝑥, 𝑦))𝑑𝑦
𝑦1
𝑦0
 
Provided that f and its partial derivative 
𝑑
𝑑𝑥
(𝑓(𝑥, 𝑦)) are both continuous over a region in 
the form (x0,x1)*(y0,y1) 
Thus by the definition of pdf and Leibniz’s rule, the pdf of 𝑍(𝑁) can be derived as  
𝑓𝑍(𝑁)(𝑧) =
𝑑
𝑑𝑧
𝐹𝑍(𝑁)(𝑧) =
𝑑
𝑑𝑧
∫ 𝛷𝑁 (
𝑥√0.5 + 𝑧
√0.5
) 𝜙(𝑥)𝑑𝑥
∞
−∞
= ∫
𝑑
𝑑𝑧
𝛷𝑁 (
𝑥√0.5 + 𝑧
√0.5
) 𝜙(𝑥)𝑑𝑥
∞
−∞
 
Let 𝑓1(𝑧) =
𝑥√0.5+𝑧
√0.5
, 𝑓2(𝑧) = 𝛷(𝑓1(𝑧)) 𝑎𝑛𝑑 𝑓3(𝑧) = 𝑓2
𝑁(𝑧) . Then by the chain rule, the 
above equation can be written as 
𝑓𝑍(𝑁)(𝑧) = ∫ 𝑓3
,(𝑧) 𝑓2
,(𝑧)𝑓1
,(𝑧)𝜙(𝑥)𝑑𝑥
∞
−∞
= ∫ 𝑁 𝑓2
𝑁−1(𝑧)𝜙(𝑓1(𝑧))𝜙(𝑥)𝑑𝑥
∞
−∞
= ∫
𝑁
√0.5
𝛷𝑁−1 (
𝑥√0.5 + 𝑧
√0.5
) 𝜙 (
𝑥√0.5 + 𝑧
√0.5
) 𝜙(𝑥)𝑑𝑥   (3.3)
∞
−∞
 
 
2) We derive the test statistic at the final analysis. Suppose Dose 𝑗 is selected at the 
interim analysis and it enters the Stage 2 with placebo.  Here we still assume the 
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variances of each treatment group are equal and all 𝜎2 = 1and a 1-1 randomization in 
both stages. We let 𝑛1 𝑎𝑛𝑑 𝑛2 be the sample size of each treatment of stage 1 and stage 2. 
And further let ?̅?1,𝑖  𝑎𝑛𝑑 ?̅?2,𝑖 , 𝑖 = 0, 𝑗 be the sample mean of treatment 𝑖 (placebo or Dose 
𝑗) of stage 1 and stage 2 respectively, then the test statistic at the final analysis is: 
𝑍𝑗 =
√𝑛1 + 𝑛2(?̅?𝑗 − ?̅?0)
√2
=
√𝑛1 + 𝑛2
√2
(
∑ 𝑋𝑗
𝑛1 + 𝑛2
−
∑ 𝑋0
𝑛1 + 𝑛2
)
=
√𝑛1 + 𝑛2
√2
(
∑ 𝑋1,𝑗 + ∑ 𝑋2,𝑗
𝑛1 + 𝑛2
−
∑ 𝑋1,0 + ∑ 𝑋2,0
𝑛1 + 𝑛2
)
=
√𝑛1 + 𝑛2
√2
(
𝑛1?̅?1,𝑗 + 𝑛2?̅?2,𝑗
𝑛1 + 𝑛2
−
𝑛1?̅?1,0 + 𝑛2?̅?2,0
𝑛1 + 𝑛2
)
=
√𝑛1 + 𝑛2
√2
(
𝑛1?̅?1,𝑗 − 𝑛1?̅?1,0
𝑛1 + 𝑛2
+
𝑛2?̅?2,𝑗 − 𝑛2?̅?2,0
𝑛1 + 𝑛2
)
=
1
√2
(
𝑛1?̅?1,𝑗 − 𝑛1?̅?1,0
√𝑛1 + 𝑛2
+
𝑛2?̅?2,𝑗 − 𝑛2?̅?2,0
√𝑛1 + 𝑛2
)
=
1
√2
[
𝑛1(?̅?1,𝑗 − ?̅?1,0)
√𝑛1 + 𝑛2
+
𝑛2(?̅?2,𝑗 − ?̅?2,0)
√𝑛1 + 𝑛2
]
= √
𝑛1
𝑛1 + 𝑛2
[
√𝑛1(?̅?1,𝑗 − ?̅?1,0)
√2
] + √
𝑛2
𝑛1 + 𝑛2
[
√𝑛2(?̅?2,𝑗 − ?̅?2,0)
√2
]
= 𝑤1𝑍1,𝑗 + 𝑤2𝑍2,𝑗 
 
where 𝑤𝑖 = √
𝑛𝑖
𝑛1+𝑛2
, 𝑖 = 1,2 and 𝑍𝑖,𝑗 , 𝑖 = 1,2 are the test statistics of dose 𝑗 of stage 𝑖. 
 
3) In this section, we derive the distribution of the final test statistic 𝑍𝑗. 
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Since Dose j is selected at the interim analysis as the “best” dose with the largest test 
statistic (smallest p-value) among all doses, its test statistic  𝑍1,𝑗 follows the distribution 
specified by (3.3), i.e., the pdf of  𝑍1,𝑗 is  
𝑓𝑍1,𝑗(𝑧1) = ∫
𝑁
√0.5
𝛷𝑁−1 (
𝑥√0.5 + 𝑧1
√0.5
) 𝜙 (
𝑥√0.5 + 𝑧1
√0.5
) 𝜙(𝑥)𝑑𝑥   
∞
−∞
 
By elementary calculus, the pdf of 𝑤1𝑍1,𝑗  can be written as 
𝑓𝑤1𝑍1,𝑗(𝑧1) =
1
𝑤1
∫
𝑁
√0.5
𝛷𝑁−1 (
𝑥√0.5 +
𝑧1
𝑤1
√0.5
) 𝜙 (
𝑥√0.5 +
𝑧1
𝑤1
√0.5
) 𝜙(𝑥)𝑑𝑥
∞
−∞
 
It is easy to see that the test statistic for stage 2 𝑍2,𝑗 follows a standard Normal 
distribution and it is can be shown that the pdf of 𝑤2𝑍2,𝑗  can be written as 
𝑓𝑤2𝑍2,𝑗(𝑧2) =
1
𝑤2
𝜙 (
𝑧2
𝑤2
) 
Next we derive the pdf of 𝑍𝑗 = 𝑤1𝑍1,𝑗 + 𝑤2𝑍2,𝑗 . For simplicity, we omit the index j. 
Let X and Y be two independent random variables with density functions 𝑓𝑋(𝑥)  and 
𝑓𝑌(𝑦) defined for all x. Then the sum Z = X + Y is a random variable with density 
function 𝑓𝑍(𝑧), where 𝑓𝑍 is the convolution of 𝑓𝑋and 𝑓𝑌 . 
𝑓𝑍(𝑧) = ∫ 𝑓𝑋(𝑧 − 𝑦)𝑓𝑌(𝑦)𝑑𝑦 =  ∫ 𝑓𝑌(𝑧 − 𝑥)𝑓𝑋(𝑥)𝑑𝑥  
∞
−∞
 
∞
−∞
 
Therefore, the pdf of 𝑍 = 𝑤1𝑍1 + 𝑤2𝑍2 can be derived as  
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𝑓𝑍(𝑧) = ∫ 𝑓𝑤1𝑍1(𝑧1)
∞
−∞
𝑓𝑤1𝑍2(𝑧 − 𝑧1)𝑑𝑧1
= ∫
1
𝑤1
∫
𝑁
√0.5
𝛷𝑁−1 (
𝑥√0.5 +
𝑧1
𝑤1
√0.5
) 𝜙 (
𝑥√0.5 +
𝑧1
𝑤1
√0.5
) 𝜙(𝑥)
1
𝑤2
𝜙 (
𝑧 − 𝑧1
𝑤2
) 𝑑𝑥
∞
−∞
∞
−∞
𝑑𝑧1
=
𝑁
√0.5𝑤1𝑤2
∫ ∫ 𝛷𝑁−1 (
𝑥√0.5 +
𝑧1
𝑤1
√0.5
) 𝜙 (
𝑥√0.5 +
𝑧1
𝑤1
√0.5
) 𝜙(𝑥)𝜙 (
𝑧 − 𝑧1
𝑤2
) 𝑑𝑥
∞
−∞
∞
−∞
𝑑𝑧1 
 
Thus by definition the cdf of the final test statistic Z is  
𝐹𝑍(𝑧) =
𝑁
√0.5𝑤1𝑤2
∫ ∫ ∫ 𝛷𝑁−1 (
𝑥√0.5 +
𝑧1
𝑤1
√0.5
) 𝜙 (
𝑥√0.5 +
𝑧1
𝑤1
√0.5
) 𝜙(𝑥)𝜙 (
𝑡 − 𝑧1
𝑤2
) 𝑑𝑥
∞
−∞
∞
−∞
𝑧
−∞
𝑑𝑧1𝑑𝑡 (3.4) 
This multiple integration (3.4) can be solved by Matlab R2013a function “integral3”. 
 
To check the validity of the distribution of the final test statistic specified in (3.4), we 
firstly simulate the distribution of the final test statistic. More precisely, we simulate the 
maximum of N (prefixed) equally correlated standardized Normal random variables and 
another standardized normal random variable. By 2) in section 3.3, their weighted 
summation is the simulated final test statistic. Next, we find the 97.5% quantile of the 
simulated data and compare it with the critical value obtained from (3.4). Table 3.1 below 
shows the final critical value calculated from (3.4) and from simulation. We can see from 
the table that the final critical values calculated from (3.4) and those from simulation 
match quite well, suggesting the validity of formula (3.4).  
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Table 3.1 Comparison of the final critical value from (3.4) v.s. from simulation 
(n1:n2) 
# of doses 
critical value from (3.4)  (critical value from simulation) 
1:1 1:2 1:3 1:4 1:5 
2 2.1676 
(2.1678) 
2.1403 
(2.1404) 
2.1218 
(2.1218) 
2.1081 
(2.1080) 
2.0976 
(2.0975) 
3  2.2781 
(2.2784) 
2.2353 
(2.2354) 
2.2065 
(2.2063) 
2.1853 
(2.1854) 
2.1690 
(2.1689) 
4 2.3523 
(2.3526) 
2.2986 
(2.2983) 
2.2627 
(2.2624) 
2.2365 
(2.2362) 
2.2163 
(2.2161) 
 
 
3.4 Simulation studies  
 
Purpose: 
To compare the Operating Characteristics (OP): Type I Error and power of ASD between 
our proposed method with combination methods and Traditional Separate Phase II and 
Phase III Design under several scenarios. The power is defined as truly finding the best 
dose, i.e., under the alternative hypothesis, the probability of rejecting the null hypothesis 
which is the best dose has the same effect with placebo.  
 
General assumptions: 
We assume a 1:1 randomization of n1 patients into N treatments group and a control 
(placebo) group in the first stage and a 1:1 randomization of n2 patients into the “best” 
treatment group selected from the interim analysis and the control (placebo) group of 
second stage. The outcomes of the treatment groups and the control group are 
independent and follow a Normal distribution with a known variance of 1. The number of 
simulations is 100,000 for the Type I error calculation and 10,000 for the power 
  
36 
calculation. A one-sided 𝛼 level test is performed during the whole process. For the Type 
I error calculation, we assume all means of the treatments group and placebo group are 0 
and for the power calculation we assume the mean of placebo group is 0.  
 
Procedures: 
(1) Traditional Separate Phase II and Phase III Design 
Firstly, we simulated N+1 independent samples and each of them has the sample size n1 
and follows a Normal distribution with pre-specified mean value (0 for the placebo 
group) and variance 1. Then at the interim analysis, we calculate the p-value for each of 
the N treatment versus placebo comparisons by using the standard Z test and select the 
treatment with the smallest p-value to enter the stage 2 with the placebo. At the interim 
analysis, we do not require the smallest p-value to be significant to continue the study.  
Next, simulate another two (new) independent Normal samples with sample size of n2 for 
each group and one with the mean value of the selected treatment and the other one of 0 
for the placebo. At the end of the study, perform a Z test solely based on the patients’ 
data from the second stage and if the test statistic is greater than the standard critical 
value of the Z test for the pre-specified 𝛼 level, then we can reject the null hypothesis of 
no effect between the best dose and placebo. 
 
(2) ASD with Combination Methods 
The process of how to simulate the data is the same with traditional separate Phase II and 
Phase III design in (1), but at the interim analysis, in addition to computing the p-values 
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for each treatment versus placebo comparison, we need to compute the intersection p-
values for the treatment with the smallest elementary p-value suggested by the Closed 
Testing Procedure. Here, since it is a multiple comparisons problem of multiple treatment 
groups with a common control group, the Dunnett Testing Procedure is applied in the 
computation of the intersection p-values. As in (1), the treatment with the smallest 
(elementary) p-value is selected to enter the second stage with the placebo. 
At the end of the second stage, as in (1) we calculate the p-value solely based on the 
patients’ data of the second stage for the comparison between selected dose versus 
placebo. Finally, we use the combination function (either Fisher’s or Inverse Normal) to 
combine this stage 2 p-value with each of the intersection p-values (including the 
elementary p-value) from stage 1 and compare with the corresponding critical value.  
Finally, we follow the Closed Testing Procedure to either reject or fail to reject the null 
hypothesis. 
 
(3) ASD with our proposed method 
As the Traditional Separate Phase II and Phase III Design in (1), the data simulation and 
the treatment selection process at the interim does not change for the ASD with our 
proposed method. The only difference exists in the final analysis. At the final analysis of 
our proposed method, we compute the regular Z statistic based on the 𝑛1 + 𝑛2 patients’ 
data for the comparison of selected treatment versus placebo. Instead of comparing this 
test statistic with the critical value for standard Z test, we need to compare it with an 
adjusted critical value by using the formula (3.4).  
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Below are the results tables from our simulation studies. We consider several scenarios of 
different numbers of doses in stage 1 and different effect sizes of the doses tested in stage 
1. 
 
Results 
Tables 3.2-3.6 below (see appendix for the complete results) present Type I error results 
for scenarios of different numbers of doses. Again, n1 and n2 in the table title are the 
sample size per treatment group for stage 1 and stage 2 respectively. The first column of 
the results table shows the number of doses N in the first stage. For example, the first row 
of Table 3.2 shows the Type I Error results for the scenario of 2 doses group and a 
placebo group in stage 1. The following 4 columns are the Type I Error results for our 
proposed method, Inverse Normal Method, Fisher’s Method and Traditional Separate 
Phase II and Phase III Design.  
Tables 3.7-3.16 below (see appendix for the complete results) present power results for 
scenarios of different numbers of doses and different sample sizes. Similar with the Type 
I Error results table, n1 and n2 in the table title are the sample size per treatment group for 
stage 1 and stage 2 respectively. The first column of the tables shows the effect size of 
the N doses in the first stage. The effect size of placebo group is always 0, so it is omitted 
from the results tables. For example, the first row of Table 3.7 shows the power results of 
2 doses group with effect size of 0 and 0.1 and a placebo group with effect size 0 
(omitted). The following 4 columns are the power results for our proposed method, 
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Inverse Normal Method, Fisher’s Method and Traditional Separate Phase II and Phase III 
Design.  
 
Table 3.2 Type I error calculation for n1=100 and n2=100 
# of doses 
in stage 1 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
2 doses 0.02498 0.02493 0.02491 0.02457 
3 doses 0.02498 0.02497 0.02498 0.02446 
4 doses 0.02473 0.02479 0.02486 0.02481 
5 doses 0.02471 0.02481 0.02496 0.02488 
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Table 3.3 Type I error calculation for n1=100 and n2=200 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
2 doses 0.02469 0.02488 0.02457 0.02477 
3 doses 0.02401 0.02418 0.02463 0.02490 
4 doses 0.0247 0.02463 0.02472 0.02445 
5 doses 0.02494 0.02493 0.02498 0.02499 
 
 
Table 3.4 Type I error calculation for n1=100 and n2=300 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
2 doses 0.02492 0.02492 0.02498 0.02455 
3 doses 0.02491 0.02493 0.02491 0.02468 
4 doses 0.02469 0.02471 0.02488 0.02439 
5 doses 0.02482 0.02484 0.02479 0.02447 
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Table 3.5 Type I error calculation for n1=100 and n2=400 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
2 doses 0.02482 0.02484 0.02488 0.02455 
3 doses 0.02486 0.02483 0.02497 0.02441 
4 doses 0.02443 0.02425 0.02487 0.02498 
5 doses 0.02455 0.02475 0.02483 0.02474 
 
Table 3.6 Type I error calculation for n1=100 and n2=500 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
2 doses 0.02499 0.02498 0.02491 0.02491 
3 doses 0.02491 0.02491 0.02492 0.02479 
4 doses 0.02481 0.02487 0.02476 0.02498 
5 doses 0.02491 0.02500 0.02495 0.02492 
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Table 3.7 Power(%) calculation for n1=100 and n2=100 (2 doses) 
Effect size 
of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0.1 11.08 11.03 10.42 7.81 
0,0.2 41.86 41.64 39.76 26.56 
0.1,0.1 17.78 17.76 16.60 10.1 
0.1,0.2 37.23 37.12 35.24 21.72 
0.2,0.2 54.66 54.73 52.02 28.52 
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Table 3.8 Power(%) calculation for n1=100 and n2=200 (2 doses) 
Effect size 
of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0.1 15.69 15.66 14.47 12.86 
0,0.2 59.26 58.99 55.94 47.6 
0.1,0.1 23.91 23.97 22.32 16.61 
0.1,0.2 51.09 50.98 48.37 38.94 
0.2,0.2 70.99 71.16 68.09 51.42 
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Table 3.9 Power(%) calculation for n1=100 and n2=300 (2 doses) 
Effect size 
of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0.1 20.58 20.51 18.54 17.53 
0,0.2 71.61 71.47 68.16 63.6 
0.1,0.1 30.19 30.26 27.83 22.75 
0.1,0.2 60.74 60.73 58.09 52.31 
0.2,0.2 82.37 82.53 79.70 68.95 
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Table 3.10 Power(%) calculation for n1=100 and n2=400 (2 doses) 
Effect size 
of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0.1 25.29 25.21 22.36 21.96 
0,0.2 79.82 79.69 76.62 74.34 
0.1,0.1 36.40 36.46 33.16 28.56 
0.1,0.2 66.78 66.75 64.48 61.36 
0.2,0.2 89.59 89.69 87.26 80.64 
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Table 3.11 Power(%) calculation for n1=100 and n2=500 (2 doses) 
Effect size 
of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0.1 29.48 29.42 25.9 26.47 
0,0.2 84.86 84.80 82.14 81.73 
0.1,0.1 41.96 41.99 37.99 34.94 
0.1,0.2 70.48 70.47 68.48 66.67 
0.2,0.2 93.98 94.05 92.13 88.47 
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Table 3.12 Power(%) calculation for n1=100 and n2=100 (3 doses) 
Effect size of 
the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0,0.2 36.87 36.52 35.13 25.08 
0,0.1,0.2 33.17 32.98 31.58 21.23 
0,0.2,0.2 49.66 49.62 47.23 28.37 
0.05,0.1,0.2 32.21 32.05 30.66 20.22 
0.2,0.2,0.2 56.24 56.54 53.70 29.06 
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Table 3.13 Power(%) calculation for n1=100 and n2=200 (3 doses) 
Effect size of 
the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0,0.2 53.54 53.12 50.38 44.89 
0,0.1,0.2 46.88 46.68 44.27 37.69 
0,0.2,0.2 66.73 66.79 63.57 50.26 
0.05,0.1,0.2 45.07 44.93 42.61 36.01 
0.2,0.2,0.2 72.06 72.45 69.57 51.38 
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Table 3.14 Power(%) calculation for n1=100 and n2=300 (3 doses) 
Effect size of 
the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0,0.2 65.8 65.42 62.11 60.27 
0,0.1,0.2 56.72 56.55 53.81 50.46 
0,0.2,0.2 78.57 78.60 75.30 67.34 
0.05,0.1,0.2 54.38 54.26 51.69 47.87 
0.2,0.2,0.2 82.94 83.23 80.49 68.81 
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Table 3.15 Power(%) calculation for n1=100 and n2=400 (3 doses) 
Effect size of 
the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0,0.2 73.83 73.58 70.46 69.79 
0,0.1,0.2 63.00 62.89 60.36 58.42 
0,0.2,0.2 85.98 85.99 83.08 78.78 
0.05,0.1,0.2 60.17 60.10 57.73 55.38 
0.2,0.2,0.2 89.63 89.79 87.47 80.73 
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Table 3.16 Power(%) calculation for n1=100 and n2=500 (3 doses) 
Effect size of 
the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
0,0,0.2 79.18 79.05 76.44 76.84 
0,0.1,0.2 67.19 67.16 65.12 64.91 
0,0.2,0.2 91.01 91.08 88.83 86.64 
0.05,0.1,0.2 64.06 64.05 62.16 61.65 
0.2,0.2,0.2 94.17 94.31 92.51 88.59 
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3.5 Conclusion and discussion 
 
In this section, we summarize the findings of the simulation studies and discuss the 
approaches.  
The results in Table 3.2-3.6 are summarized in Figures 3.1-3.4 below and each of the 
figures corresponds to different number of doses in stage 1. 
From results tables and figures, we find that Type I Error of our proposed method is 
maintained at nominal level as well as the Inverse Normal Method, Fisher’s Method and 
the Traditional Separate Phase II and Phase III Design. 
 
 
Figure 3.1 Type I Error for 2 Doses Study 
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Figure 3.2 Type I Error for 3 Doses Study 
 
 
Figure 3.3 Type I Error for 4 Doses Study 
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Figure 3.4 Type I Error for 5 Doses Study 
 
 
The power results can be found in the Tables 3.7-3.16. Overall, our proposed method has 
similar power to the Inverse Normal Method for every effect size and dosage setup. Both 
of them are more powerful than the Fisher’s Method and the Traditional Separate Phase 
II and Phase III Design.  
Comparing the same dosage/effect size setup across different sample sizes, we see a trend 
of how the power varies as the sample size of stage 2 increases for these 4 methods. Here, 
for simplicity but without loss of generality, we suppose the sample size of stage 1 is 
fixed at 100 per dose group and we only increase the sample size of stage 2. For the 
design with similar or slightly larger stage 2 sample size compared with stage 1, the 
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advantage, in terms of power, of our proposed method, the Inverse Normal Method and 
Fisher’s Method in comparison to the traditional method is quite obvious. However, the 
difference in power declines as the stage 2 sample size increases. Especially, when the 
sample size of stage 2 is 5 times larger than the sample size of stage 1, the Fisher’s 
Method and Traditional Separate Phase II and Phase III Design show similar power. 
Figures 3.5-3.9 below show the trend by using the power results of 3 doses with different 
effect size setups. We see from these figures that the difference in power shrinks as the 
sample size of stage 2 increases. Therefore, if the sample size of stage 2 is relatively big 
(5 times or more) compared to the sample size of stage 1, we need to balance the 
complexity and gain in power when selecting between ADS and the Traditional Separate 
Phase II and Phase III Design.   
 
Figure 3.5 Power for 3 Doses Study with the dose effect size of 0, 0, 0.2 
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Figure 3.6 Power for 3 Doses Study with the dose effect size of 0, 0.1, 0.2 
 
 
 
Figure 3.7 Power for 3 Doses Study with the dose effect size of 0, 0.2, 0.2 
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Figure 3.8 Power for 3 Doses Study with the dose effect size of 0.05, 0.1, 0.2 
 
 
 
Figure 3.9 Power for 3 Doses Study with the dose effect size of 0.2, 0.2, 0.2 
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Chapter 4. Sample size Re-estimation (SSR) 
 
4.1 Introduction 
 
In the study design stage, some of the important information used to design the trial is not 
available or is available but with a high degree of uncertainty. For example, the initial 
estimates of variance, the treatment effect desired to be detected or a control group event 
rate for a binary outcome, which all have an impact on the ability of the trial to address 
its primary objective (Shi, 2001). As a result, it is important to check the validity of these 
assumptions using the interim data and to make adjustments if necessary. One such 
adjustment is the sample size re-estimation. 
 
 
4.2 General power and sample size calculation 
 
For simplicity, suppose that we perform a 1-1 randomization of n patients in an 
experimental treatment group and a control treatment group. And a normally distributed 
response with mean 𝜇1 and variance 𝜎1
2  is observed on the patients who receive the 
experimental treatment and similarly a normally distributed response with mean 𝜇2 and 
variance 𝜎2
2 is observed on the patients who receive the control treatment. For simplicity, 
we further assume the variance from each group is known and 𝜎1
2 = 𝜎2
2 = 𝜎2. Let ?̅?1and 
?̅?2denote the sample mean response of the experimental and control groups respectively. 
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Let us consider the null hypothesis: 𝐻0: 𝜇1 − 𝜇2 = 0 against the one sided alternative 
hypothesis 𝐻𝑎: 𝜇1 − 𝜇2 ≥ 0. Let 𝛿 > 0 be the true effect difference in means that we 
want to detect. It is easy to show that the test statistic for testing H0 can be written as 
𝑍 =
?̅?1−?̅?2
𝜎√2/𝑛
 . Under the null hypothesis, it follows a standard normal distribution with pdf 
𝜙(𝑥) 𝑎𝑛𝑑 and cdf 𝛷(𝑥). Let 𝑍𝛼 = 𝛷
−1(1 − 𝛼) denote the upper 𝛼 quantile of a standard 
normal distribution. Then for a one sided size 𝛼 test, we need to achieve: 𝑃𝑟(𝑍 >
𝑐|𝑛𝑢𝑙𝑙) ≤ 𝛼. Since under the null, Z follows a standard normal distribution, the critical 
value is 𝑐 = 𝛷−1(1 − 𝛼) = 𝑍𝛼. By the power definition, if we want to achieve 1
power, we require: 
Pr(𝑍 > 𝑐|𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑣𝑒 ℎ𝑦𝑝𝑜𝑡ℎ𝑒𝑠𝑖𝑠) ≥ 1 − 𝛽 
𝑃𝑟 (
?̅?1 − ?̅?2
𝜎√2/𝑛
> 𝑍𝛼| 𝜇1 − 𝜇2 = 𝛿) ≥ 1 − 𝛽 
𝑃𝑟 (
?̅?1 − ?̅?2 − 𝛿
𝜎√2/𝑛
> 𝑍𝛼 −
𝛿
𝜎√2/𝑛
) ≥ 1 − 𝛽 
When the alternative hypothesis is true, 
?̅?1−?̅?2−𝛿
𝜎√2/𝑛
 follows a standard normal distribution. 
Hence, 
1 − 𝛷 (𝑍𝛼 −
𝛿
𝜎√2/𝑛
) ≥ 1 − 𝛽 
𝛷 (𝑍𝛼 −
𝛿
𝜎√2/𝑛
) ≤ 𝛽 
𝑍𝛼 −
𝛿
𝜎√2/𝑛
≤ 𝛷−1(𝛽) = −𝛷−1(1 − 𝛽) = −𝑍𝛽 
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𝛿
𝜎√2/𝑛
≥ 𝑍𝛼 + 𝑍𝛽 
√
𝑛
2
≥
(𝑍𝛼 + 𝑍𝛽)𝜎
𝛿
 
𝑛
2
≥ [
(𝑍𝛼 + 𝑍𝛽)𝜎
𝛿
]
2
 
                                           𝑛 ≥ 2 [
(𝑍𝛼 + 𝑍𝛽)𝜎
𝛿
]
2
                             (4.1) 
 
Example 4.1, for a fixed 1:1 clinical trial design, we assume a one-sided 𝛼 = 0.025 test 
of equality of two normal means 𝜇1 = 220, 𝜇2 = 200 𝑎𝑛𝑑 𝜎 = 30. 
To achieve 80% power, by formula 4.1, we have 
𝑛 =
2(𝑍𝛼 + 𝑍𝛽)
2
𝜎2
𝛿2
=
2(1.96 + 0.84)2302
202
= 36 𝑝𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 
 
 
4.3 Sample Size Re-estimation (SSR) 
 
SSR is usually performed at the interim analysis in the group sequential design (Jennison, 
1999). The sample size may be recalculated using an estimate of the variance at the 
interim analysis.  As the general sample size calculation, we are still assuming a one-
sided test of equality of two normal means with a common within-group variance of 𝜎2. 
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For simplicity and without loss of generality, we assume one interim analysis and one 
final analysis and the interim analysis is at the 50% information time.  At the interim 
analysis, the pre-study variance estimate is updated and based on that the sample size is 
recalculated.  
Example 4.2: Continuing from the last example, suppose at the interim analysis we 
calculate the standard deviation from the accumulated data and let it be 𝑠1 = 35. We 
replace the pre-study estimate of 30 and recalculate the total sample size per group: 
𝑛 =
2(𝑍𝛼 + 𝑍𝛽)
2
𝜎2
𝛿2
=
2(1.96 + 0.84)2352
202
= 48 𝑝𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 
This SSR approach answers the question “How many observations would I take if I was 
to run this study again?” However, when the SSR is being conducted, patients’ data of 
the first stage is available and the total sample size should be determined given the 
information from the first stage. In other word, we are interested in a more specific 
question “How many further observations do I need to take in this particular study?”  
Denne (2001) gave an answer to this question by incorporating the Conditional Power 
(CP) into SSR.  
 
 
4.4 Sample size re-estimation based on conditional power 
4.4.1 Denne’s method 
Denne (2001) proposed a sample size re-estimation method based on conditional power. 
We illustrate this method by using a standard group sequential design with a single 
interim analysis.  
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Again, let us consider the null hypothesis: 𝐻0: 𝜇𝑋 − 𝜇𝑌 = 0 against the one sided 
alternative hypothesis 𝐻𝑎 : 𝜇𝑋 − 𝜇𝑌 ≥ 𝛿, where 𝛿 > 0 is the smallest effect difference in 
means that we want to detect. Similar to the general power and sample size calculation 
presented above, at the first stage (before the interim analysis), suppose that we perform a 
1-1 randomization of n1 patients in each of an experimental treatment group and a control 
treatment group. And a normal response with mean 𝜇𝑋  and variance 𝜎𝑋
2 is observed on 
the patients who receive the experimental treatment and similarly a normal response with 
mean 𝜇𝑌 and variance 𝜎𝑌
2 is observed on the patients who receive the control treatment. 
For simplicity, we further assume the variance from each group is known and 𝜎𝑋
2 = 𝜎𝑌
2 =
𝜎2. Our goal is to determine the additional sample size n2 per treatment group for the 
second stage and the adjusted critical value c such that the overall type one error rate can 
be maintained at the nominal level and achieve the pre-specified 1 − 𝛽 conditional 
power.  
Let ?̅?𝑖 and ?̅?𝑖 denote the sample mean response of the experimental and control groups 
from the 𝑛𝑖  patients (𝑖 = 1,2). We further assume ?̅? and ?̅? to be the sample mean 
response of the experimental and control groups from the total 𝑛1 + 𝑛2  patients. It is easy 
to show that at the final analysis, the test statistic for testing H0 can be written as  
𝑍 =
?̅?−?̅?
𝜎√2/(𝑛1+𝑛2)
=
∑ 𝑋
𝑛1+𝑛2
−
∑ 𝑌
𝑛1+𝑛2
𝜎√2/(𝑛1+𝑛2)
=
(𝑛1?̅?1+𝑛2?̅?2)−(𝑛1?̅?1+𝑛2?̅?2)
𝜎√2(𝑛1+𝑛2)
=
(𝑛1?̅?1−𝑛1?̅?1)+(𝑛2?̅?2−𝑛2?̅?2)
𝜎√2(𝑛1+𝑛2)
=
𝑛1(?̅?1−?̅?1)+𝑛2(?̅?2−?̅?2)
𝜎√2(𝑛1+𝑛2)
=
𝑍1𝜎√2𝑛1+𝑛2(?̅?2−?̅?2)
𝜎√2(𝑛1+𝑛2)
   , 𝑤ℎ𝑒𝑟𝑒  𝑍1 =
?̅?1−?̅?1
𝜎√2/𝑛1
  
Let 𝐶𝑃𝛿(𝑛2,𝑐|𝑧1) denote the probability that Z based on n1+n2 observations exceeds the 
critical value c given that 𝑍1 = 𝑧1. 
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𝐶𝑃𝛿(𝑛2,𝑐|𝑧1) = 𝑃𝑟(𝑍 > 𝑐|𝑍1, 𝛿) = 𝑃𝑟 (
𝑛1(?̅?1 − ?̅?1) + 𝑛2(?̅?2 − ?̅?2)
𝜎√2(𝑛1 + 𝑛2)
> 𝑐| 𝑍1 = 𝑧1, 𝛿)
= 𝑃𝑟 (
𝑧1𝜎√2𝑛1 + 𝑛2(?̅?2 − ?̅?2)
𝜎√2(𝑛1 + 𝑛2)
> 𝑐| 𝛿)
= 𝑃𝑟(𝑛2(?̅?2 − ?̅?2) > 𝑐𝜎√2(𝑛1 + 𝑛2) − 𝑧1𝜎√2𝑛1|𝛿)
= 𝑃𝑟 (?̅?2 − ?̅?2 >
𝑐𝜎√2(𝑛1 + 𝑛2) − 𝑧1𝜎√2𝑛1
𝑛2
| 𝛿)
= 𝑃𝑟 ((?̅?2 − ?̅?2) − 𝛿 >
𝑐𝜎√2(𝑛1 + 𝑛2) − 𝑧1𝜎√2𝑛1 − 𝑛2𝛿
𝑛2
)
= 𝑃𝑟 (
(?̅?2 − ?̅?2) − 𝛿
𝜎√2/𝑛2
>
𝑐𝜎√2(𝑛1 + 𝑛2) − 𝑧1𝜎√2𝑛1 − 𝑛2𝛿
𝑛2𝜎√2/𝑛2
)
= 𝑃𝑟 (
(?̅?2 − ?̅?2) − 𝛿
𝜎√2/𝑛2
>
𝑐𝜎√2(𝑛1 + 𝑛2) − 𝑧1𝜎√2𝑛1 − 𝑛2𝛿
𝜎√2𝑛2
) 
Since under the alternative hypothesis 𝐻𝑎: 𝜇𝑋 − 𝜇𝑌 ≥ 𝛿, then 𝑍2 =
(?̅?2−?̅?2)−𝛿
𝜎√2/𝑛2
 follows a 
standard normal distribution. So  
𝐶𝑃𝛿(𝑛2,𝑐|𝑧1) = 𝑃𝑟 (
(?̅?2 − ?̅?2) − 𝛿
𝜎√2/𝑛2
>
𝑐𝜎√2(𝑛1 + 𝑛2) − 𝑧1𝜎√2𝑛1 − 𝑛2𝛿
𝜎√2𝑛2
)
= 1 − 𝛷 (
𝑐𝜎√2(𝑛1 + 𝑛2) − 𝑧1𝜎√2𝑛1 − 𝑛2𝛿
𝜎√2𝑛2
)                                  (4.2) 
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4.4.2 Protecting the Type I Error   
When we re-estimate the sample size of stage 2 to achieve the 80% conditional power by 
using (4.2), we introduce a dependency between n2 and z1. Therefore, the Type I Error 
will become inflated if there is no adjustment of the critical value of the final analysis.  
Let 𝑛𝑡 be the initial target sample size calculated at protocol design stage and 𝑐̃ be our 
originally-specified final critical value. To protect the Type I Error, Denne (2001) 
suggests to find 𝑛2 and a revised critical value c such that 
𝐶𝑃𝛿=0(𝑛2,𝑐|𝑧1) = 𝐶𝑃𝛿=0(𝑛𝑡,𝑐̃|𝑧1) 
 
1 − 𝛷 (
𝑐𝜎√2(𝑛1 + 𝑛2) − 𝑧1𝜎√2𝑛1
𝜎√2𝑛2
) = 1 − 𝛷 (
𝑐̃𝜎√2(𝑛1 + 𝑛𝑡) − 𝑧1𝜎√2𝑛1
𝜎√2𝑛𝑡
) 
 
𝑐√𝑛1 + 𝑛2 − 𝑧1√𝑛1
√𝑛2
=
𝑐̃√𝑛1 + 𝑛𝑡 − 𝑧1√𝑛1
√𝑛𝑡
 
 
𝑐 =
√𝑛2 (
𝑐̃√𝑛1 + 𝑛𝑡 − 𝑧1√𝑛1
√𝑛𝑡
) + 𝑧1√𝑛1
√𝑛1 + 𝑛2
 
 
𝑐 = 𝑐̃√
(𝑛1 + 𝑛𝑡)𝑛2
𝑛𝑡(𝑛1 + 𝑛2)
− 𝑧1√
𝑛1
𝑛1 + 𝑛2
(√
𝑛2
𝑛𝑡
− 1)                   (4.3) 
 
Formula (4.3) fixes the Type I Error inflation caused by the dependence between n2 and 
z1, but if we consider SSR within the framework of ASD, we have to further adjust the 
final critical value for multiple comparisons. We discuss the detailed procedures in the 
simulations studies in the next section. 
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4.5 Simulation studies  
 
Purpose: 
To investigate the OP (Type I Error and general power) and the sample size after SSR 
based on CP within the framework of our proposed method for ASD.  
 
General assumptions: 
We assume a 1:1 randomization of n1 patients into N treatments group and a control 
(placebo) group of first stage and a 1:1 randomization of n2 patients into the “best” 
treatment group selected from the interim analysis and the control (placebo) group of 
second stage. The outcomes of the treatment groups and the control group are 
independent and follow a Normal distribution with a known variance of 1. Since we use 
an iteration method to perform the SSR, the simulations take much more time than the 
fixed sample size design. Based on the running time limits, the number of simulations are 
20000 for the Type I error calculations and 5000 for the power calculation. We further 
assume a flat dose response rate to calculate the initial sample size and in the conditional 
power calculation (for the case of using prefixed mean scenario). We will discuss the 
details in the next section. 
Procedures: 
(1) Initial total sample size (nT) is determined to achieve 80% power and one sided 0.025 
test for a fixed design by using the general sample size calculation (4.1).  
(2) We next simulated N+1 independent samples and each of them has a prefixed sample 
size n1 (100) and follows a Normal distribution with pre-specified mean value (0 for the 
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placebo group) and variance 1. Then at the interim analysis, we calculate the p-value for 
each of the N treatment versus placebo comparisons using the regular Z test and select 
the treatment with the smallest p-value to enter the second stage with the placebo.  
(3) After obtaining the test statistic Z1 from the first stage, we set the initial sample size 
for the second stage by 𝑛𝑇 − 𝑛1 and calculate the final critical value 𝑐?̃?𝑆𝐷 using formula 
(3.4) and revise ?̃?𝐴𝑆𝐷 using formula (4.3) and we call the revised critical value 𝑐𝑆𝑆𝑅 . Let 
the final critical value 𝑐 = 𝑚𝑎𝑥(𝑐?̃?𝑆𝐷 , 𝑐𝑆𝑆𝑅). By formula (4.2), calculate CP using the 
final critical value c. Here, in the conditional power calculation we explore two cases: (i) 
using a prefixed mean as the true mean difference and (ii) using an estimated mean as the 
true mean difference. In (i), we use the prefixed mean for the initial total sample size 
calculation, and we assume a flat dose response (all doses have the same mean value) so 
the value does not depend on what treatment is selected at the interim. On the other hand, 
in case (ii) we used the estimated mean difference between the treatment group selected 
at the interim with the placebo group from the first stage data. Note for this scenario, if 
this estimated mean difference is negative, we stop the trial and claim futility since we 
use this estimated value as the true mean difference.  
 (4) In some of the scenarios we considered, we built in a pre-fixed futility bound of 10% 
for the initial CP, i.e., if the initial CP is less than 10%, we stop the trial and claim 
futility. Otherwise, increase sample size (n2) for the second stage and repeat step (3) until 
it achieves the 80% CP. Also in some of the scenarios we considered, we set a maximum 
sample size for stage 2 as 3 times the initial value. 
  
67 
(5) Finally, for each group we simulate another two (new) independent Normal samples 
with the sample size n2 we get from step (4) and one sample with the mean value of the 
selected treatment and the other one of 0 for the placebo. At the final analysis, we 
compute the regular Z statistic based on n1+n2 observations for the comparison of 
selected treatment versus placebo. Instead of comparing this test statistic with the critical 
value for standard Z test, we compare it with adjusted critical value c we get from step 
(3).  
 
Results 
Some notations of the table header: 
“Futility bound”: 10% (see step (4) for details) 
“max n”: 3*(nT-n1) (see step (4) for details) 
“Prefixed mean diff for the initial n and CP”: prefixed mean difference for the initial 
sample size and CP calculation (using prefixed mean difference as the true mean 
difference) 
“Prefixed mean diff for the initial n”: prefixed mean difference for the initial sample size 
calculation (using estimated mean difference as the true mean difference) 
 “Average Sample Size per dose after SSR”: average total sample size per group after 
SSR over simulations. 
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Table 4.1 Sample size re-estimation by CP (using prefixed mean) 
Effect 
size of 
doses 
Prefixed mean 
diff for the 
initial n and CP 
Type I 
Error 
Initial Sample Size 
per dose  
Average Sample Size 
per dose after SSR 
0,0 0.1 0.02405 1570 1841 
0,0 0.2 0.02295 393 620 
Effect 
size of 
doses 
Prefixed mean 
diff for the 
initial n and CP 
Power 
(%) 
Initial Sample Size 
per dose  
Average Sample Size 
per dose after SSR 
0.1,0.2 0.1 75.26 1570 1633 
0.1,0.2 0.2 63.86 393 462 
0.1,0.1 0.1 83.58 1570 1692 
0.2,0.2 0.2 87.68 393 439 
0,0.2 0.1 93.28 1570 1654 
0,0.2 0.2 78.8 393 477 
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Table 4.2 Sample size re-estimation by CP (using prefixed mean) 
Effect 
size of 
doses 
Prefixed mean diff for the 
initial n and CP 
Type I 
Error 
Initial Sample 
Size per dose  
Average 
Sample Size 
per dose after 
SSR 
0,0 0.1 0.02405 1570 1841 
0,0 0.2 0.0239 393 622 
Effect 
size of 
doses 
Prefixed mean diff for the 
initial n and CP 
Power 
(%) 
Initial Sample 
Size per dose  
Average 
Sample Size 
per dose after 
SSR 
0.1,0.2 0.1 75.26 1570 1633 
0.1,0.2 0.2 66.3 393 464 
0.1,0.1 0.1 83.58 1570 1692 
0.2,0.2 0.2 87.96 393 439 
0,0.2 0.1 93.28 1570 1654 
0,0.2 0.2 78.54 393 476 
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Table 4.3 Sample size re-estimation by CP (using prefixed mean) 
Effect 
size of 
doses 
Prefixed mean diff for the 
initial n and CP 
Type I 
Error 
Initial Sample 
Size per dose  
Average Sample 
Size per dose 
after SSR 
0,0 0.1 0.02405 393 631 
0,0 0.2 0.0248 1570 1841 
Effect 
size of 
doses 
Prefixed mean diff for the 
initial n and CP 
power (%) Initial Sample 
Size per dose  
Average Sample 
Size per dose 
after SSR 
0.1,0.2 0.1 75.26 1570 1633 
0.1,0.2 0.2 64.86 393 464 
0.1,0.1 0.1 83.58 1570 1692 
0.2,0.2 0.2 87.66 393 440 
0,0.2 0.1 93.28 1570 1654 
0,0.2 0.2 78.8 393 480 
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Table 4.4 Sample size re-estimation by CP (using estimated mean) 
Build in futility bound and max n 
Effect size 
of doses 
Prefixed mean diff 
for the initial n 
Type I 
Error 
Initial Sample 
Size per dose  
Average Sample 
Size per dose after 
SSR 
0,0 0.1 0.01995 1570 2228 
0,0 0.2 0.02035 393 586 
Effect size 
of doses 
Prefixed mean diff 
for the initial n 
power  
(%) 
Initial Sample 
Size per dose  
Average Sample 
Size per dose after 
SSR 
0.1,0.2 0.1 71.02 1570 1786 
0.1,0.2 0.2 59.2 393 520 
0.1,0.1 0.1 72.52 1570 1952 
0.2,0.2 0.2 82.44 393 485 
0,0.2 0.1 83 1570 1830 
0,0.2 0.2 69.82 393 521 
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Table 4.5 Sample size re-estimation by CP (using estimated mean) 
Build in futility bound but no max n 
Effect size 
of doses 
Prefixed mean diff 
for the initial n 
Type I 
Error 
Initial Sample 
Size per dose  
Average Sample 
Size per dose after 
SSR 
0,0 0.1 0.02015 1570 2917 
0,0 0.2 0.02415 393 768 
Effect size 
of doses 
Prefixed mean diff 
for the initial n 
power  
(%) 
Initial Sample 
Size per dose  
Average Sample 
Size per dose after 
SSR 
0.1,0.2 0.1 70.02 1570 2046 
0.1,0.2 0.2 60.42 393 596 
0.1,0.1 0.1 71.16 1570 2180 
0.2,0.2 0.2 83.6 393 532 
0,0.2 0.1 83.72 1570 2057 
0,0.2 0.2 70.14 393 608 
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Table 4.6 Sample size re-estimation by CP (using estimated mean) 
Build in max n but no futility bound 
Effect size 
of doses 
Prefixed mean diff 
for the initial n 
Type I 
Error 
Initial Sample 
Size per dose  
Average Sample 
Size per dose after 
SSR 
0,0 0.1 0.021 1570 2607 
0,0 0.2 0.0245 393 803 
Effect size 
of doses 
Prefixed mean diff 
for the initial n 
power 
(%) 
Initial Sample 
Size per dose  
Average Sample 
Size per dose after 
SSR 
0.1,0.2 0.1 72.28 1570 1878 
0.1,0.2 0.2 67.02 393 573 
0.1,0.1 0.1 77.96 1570 2117 
0.2,0.2 0.2 88.6 393 522 
0,0.2 0.1 86.32 1570 1925 
0,0.2 0.2 77.78 393 591 
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4.6 Conclusion and discussion 
Tables 4.1-4.3 contain the results using prefixed mean to calculate CP and Table 4.4-
Table 4.6 contain the results using estimated mean to calculated CP. For both methods, 
the Type I Error is successfully maintained at the nominal level. As the simulation study 
in Chapter 3, the power is defined as truly finding the best dose, i.e., under the alternative 
hypothesis, the probability of rejecting the null hypothesis which is the best dose has the 
same effect with placebo. Given the nature of this power definition, we may “lose” some 
power if we select the wrong dose as the best dose at the interim analysis for some 
scenarios. Moreover, the power may decrease due to the futility bound and maximum 
sample size bound built into the analyses. For most of the scenarios, if we “correctly” 
select the mean value for the initial sample size and CP calculation (prefixed mean 
scenario), our proposed method has good performance in terms of power after SSR. 
Comparing the two methods, the “prefixed mean” method performs better than the 
“estimated mean” method in terms of power, because the “estimated mean” method uses 
estimated mean as the true mean when calculating the CP which sometimes lead to low 
CP or very big sample size that may fail the trial by the futility bound or max n. 
 
Sensitivity Analysis 
To check the sensitivity of our proposed method to the normality assumption, we perform 
a simulation study with a skewed distribution.  In a medical cardiovascular device clinical 
trial on patients with stenosis, the primary endpoint “Total Lesion Volume” (TLV) is the 
volume of a blocked lesion in the artery, where a value of 0 is desired. Since, after 
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treatment with the device, there are a lot of 0’s, this TLV data has been shown to follow a 
Weibull distribution which has a pdf 𝑓(𝑥) =
𝑎
𝑏𝑎
𝑥𝑎−1𝑒−(
𝑥
𝑏
)
𝑎
, where a and b are the shape 
and scale parameter.   
We follow the same procedure specified in section 4.5 and use the real life values (mean 
and standard deviation) of TLV shown in Table 4.7 for the simulation study. For 
simplicity, we only consider 2 doses groups and a placebo group in stage 1 and still 
assume the same standard deviation among all 3 groups. And we use the prefixed mean 
for initial sample size and CP calculation and build in the 10% futility bound and 
maximum sample size bound. 
 
Table 4.7 Simulation Setups for the Sensitivity Analysis 
Scenario Mean (SD) for 
placebo 
Mean (SD) for 
dose 1 
Mean (SD) for 
dose 2 
Scenario 1 (Type I Error) 1.4(1.65) 1.4(1.65) 1.4(1.65) 
Scenario 2 (Power) 1.4(1.65) 1.4(1.65) 1.1(1.65) 
Scenario 3 (Power) 1.4(1.65) 1.1(1.65) 1.1(1.65) 
     
Table 4.8 below shows the results of the simulation study. From the results table we find 
that, for the Weibull distribution, our proposed method can still control the Type I Error 
at nominal level. However, we find low power when using our proposed method for the 
Weibull distribution even after SSR. In summary, from this sensitivity analysis we 
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conclude that our proposed method is sensitive to the normality assumption in terms of 
power but not for Type I Error.     
 
Table 4.8 Results of the Sensitivity Analysis 
Scenario Prefixed mean 
diff for the 
initial n and CP 
Type I 
Error 
Initial Sample 
Size per dose  
Average Sample Size 
per dose after SSR 
Scenario 1 0.3 0.025 175 282 
Scenario Prefixed mean 
diff for the 
initial n and CP 
Power 
(%) 
Initial Sample 
Size per dose  
Average Sample Size 
per dose after SSR 
Scenario 2 0.3 35.96 175 250 
Scenario 3 0.3 49.08 175 230 
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Chapter 5. Overall Conclusion and Discussion 
The purpose of this chapter is to summarize the contribution of this dissertation and 
propose future work that can be carried out to supplement and improve the methods and 
application proposed and investigated in this dissertation. The research was initiated by 
theoretically reviewing two commonly used approaches in the adaptive seamless designs 
including the methodologies of multiple comparisons. These approaches combine the 
stagewise p-values and apply the closed testing procedure to control the familywise error 
rate at the nominal level.  To make the ASD easier to understand and implement, a novel 
approach using the exact distribution of the final test statistic was then developed. The 
derivation used the distribution function of the maximum of correlated normal variables 
proposed by Gupta(1963). Simulation studies were conducted to evaluate the operating 
characteristics including type I error and power among the traditional separate Phase II 
and Phase III design, ASD with combination methods and ASD with our proposed 
method. The type I error is well controlled for all of the methods. For the power 
comparisons, our proposed method has similar power with the inverse normal method, 
and both of them are slightly more powerful than Fisher’s method. As expected, the 
traditional separate Phase II and Phase III design performs the worst among the four 
designs especially for sample size ratio larger than 1:5. 
Next, we explore the sample size re-estimation by using the conditional power (Denne, 
2001) within the framework of our proposed method for ASD. We showed in simulation 
studies that, by using the final critical value from our method combined with the further 
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adjustment by Denne’s method, the type I error is well controlled.  It was shown in the 
simulation studies as well that the desired power can also be achieved. 
This dissertation mainly focuses on the normal endpoint, so as a future study, we can 
extend our method to binary endpoint and time to event endpoint. Furthermore, the 
adaptation of switching endpoint at the interim analysis can also be considered. For 
example, a short term endpoint (eg. normal or binary) is used in Phase II and a long term 
endpoint (eg. time to event) endpoint is used in Phase III. For the sample size re-
estimation, we only applied Denne’s method in this dissertation. It can be extended to 
more methods proposed by Cui et al. (1999), Gang Li et al. (2002), Lehmacher and 
Wassmer (1999), Proschan et al. (2005), Lan and Trost (1997), and Bauer and Kohne 
(1994).  
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APPENDIX 
Table A3.1 Type I error calculation for n1=100 and n2=600 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
2 doses 0.02486 0.02499 0.02488 0.02437 
3 doses 0.02483 0.02477 0.02489 0.02497 
4 doses 0.02475 0.02463 0.02478 0.02461 
5 doses 0.02485 0.02478 0.02497 0.02494 
 
 
 
Table A3.2 Type I error calculation for n1=100 and n2=700 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
2 doses 0.02477 0.02475 0.02445 0.0246 
3 doses 0.02490 0.02479 0.02494 0.02490 
4 doses 0.02497 0.02495 0.02496 0.02436 
5 doses 0.02482 0.02488 0.02474 0.02397 
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Table A3.3 Type I error calculation for n1=20 and n2=40 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase 
II and Phase III Design 
2 doses 0.02499 0.02494 0.0248 0.02456 
3 doses 0.02427 0.02422 0.0242 0.02492 
4 doses 0.02473 0.02478 0.02485 0.02496 
5 doses 0.02488 0.02491 0.02462 0.02495 
 
 
Table A3.4 Type I error calculation for n1=20 and n2=100 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase II 
and Phase III Design 
2 doses 0.024852 0.02487 0.02495 0.02494 
3 doses 0.02489 0.02473 0.02486 0.02442 
4 doses 0.02484 0.02481 0.02496 0.02464 
5 doses 0.02488 0.02496 0.02489 0.02434 
 
 
 
  
81 
Table A3.5 Type I error calculation for n1=20 and n2=200 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase II 
and Phase III Design 
2 doses 0.02484 0.02485 0.02483 0.02496 
3 doses 0.02494 0.0249 0.02508 0.02442 
4 doses 0.02471 0.02487 0.02491 0.02486 
5 doses 0.02498 0.0249 0.02474 0.02434 
 
 
Table A3.6 Type I error calculation for n1=20 and n2=1000 
# of doses 
in stage 1 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase II 
and Phase III Design 
2 doses 0.02489 0.02485 0.02498 0.0247 
3 doses 0.02488 0.02478 0.02457 0.02464 
4 doses 0.02494 0.02488 0.02492 0.02495 
5 doses 0.02461 0.02456 0.02455 0.02452 
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Table A3.7 Type I error calculation for n1=20 and n2=2000 
# of doses 
in stage 1 
Our 
method 
Inverse Normal 
Method 
Fisher’s 
Method 
Traditional Separate Phase II 
and Phase III Design 
2 doses 0.02488 0.02487 0.02498 0.02497 
3 doses 0.02497 0.02498 0.02489 0.02497 
4 doses 0.02467 0.02458 0.02462 0.02479 
5 doses 0.02482 0.02478 0.02476 0.02489 
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Table A3.8 Power(%) calculation for n1=100 and n2=100 (4 doses) 
Effect size of the 
doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0.2 33.25 32.78 31.75 24.11 
0,0,0.1,0.2 30.18 29.83 28.63 20.3 
0,0,0.2,0.2 45.66 45.57 43.43 27.62 
0,0.2,0.2,0.2 52.50 52.78 50.21 28.59 
0.025,0.05,0.1,0.2 29.02 28.81 27.55 19.04 
0.2,0.2,0.2,0.2 56.61 57.13 54.45 28.85 
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Table A3.9 Power(%) calculation for n1=100 and n2=200 (4 doses) 
Effect size of the 
doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0.2 49.70 49.11 46.70 42.36 
0,0,0.1,0.2 44.04 43.67 43.46 36.22 
0,0,0.2,0.2 63.23 63.05 60.09 49.21 
0,0.2,0.2,0.2 69.04 69.33 66.38 50.83 
0.025,0.05,0.1,0.2 41.95 41.64 39.51 34.01 
0.2,0.2,0.2,0.2 72.38 72.88 70.21 51.39 
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Table A3.10 Power(%) calculation for n1=100 and n2=300 (4 doses) 
Effect size of the 
doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0.2 61.31 60.80 57.76 56.64 
0,0,0.1,0.2 53.45 53.17 50.53 48.11 
0,0,0.2,0.2 75.20 75.14 71.86 65.95 
0,0.2,0.2,0.2 80.43 80.65 77.73 68.08 
0.025,0.05,0.1,0.2 50.67 50.46 47.97 45.37 
0.2,0.2,0.2,0.2 89.99 83.39 80.90 68.75 
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Table A3.11 Power(%) calculation for n1=100 and n2=400 (4 doses) 
Effect size of the 
doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0.2 69.51 69.13 66.09 66.67 
0,0,0.1,0.2 60.25 60.01 57.50 56.26 
0,0,0.2,0.2 83.37 83.26 80.29 77.16 
0,0.2,0.2,0.2 87.83 83.95 85.37 79.75 
0.025,0.05,0.1,0.2 56.86 56.68 54.35 52.51 
0.2,0.2,0.2,0.2 89.94 90.16 87.98 80.55 
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Table A3.12 Power(%) calculation for n1=100 and n2=500 (4 doses) 
Effect size of the 
doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0.2 75.05 74.86 72.29 73.7 
0,0,0.1,0.2 64.48 64.38 62.34 62.62 
0,0,0.2,0.2 88.60 88.62 86.21 85.04 
0,0.2,0.2,0.2 92.62 92.78 90.72 87.75 
0.025,0.05,0.1,0.2 60.76 60.69 58.84 58.77 
0.2,0.2,0.2,0.2 94.32 94.50 92.71 88.71 
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Table A3.13 Power(%) calculation for n1=100 and n2=100 (5 doses) 
Effect size of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0,0.2 30.89 30.42 29.54 22.69 
0,0,0,0.1,0.2 28.27 27.95 26.90 19.62 
0,0,0,0.2,0.2 43.33 43.16 41.08 26.71 
0,0,0.2,0.2,0.2 49.85 50.04 47.43 27.96 
0,0.2,0.2,0.2,0.2 54.14 54.59 51.79 28.83 
0.2,0.2,0.2,0.2,0.2 57.25 57.86 55.06 28.61 
0.0125,0.025,0.05,0.1,0.2 27.23 27.00 25.88 18.42 
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Table A3.14 Power(%) calculation for n1=100 and n2=200 (5 doses) 
Effect size of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0,0.2 46.45 45.79 43.61 40.32 
0,0,0,0.1,0.2 41.65 41.16 39.15 34.52 
0,0,0,0.2,0.2 60.61 60.40 57.43 47.89 
0,0,0.2,0.2,0.2 66.99 67.13 64.10 50.09 
0,0.2,0.2,0.2,0.2 70.5 70.90 68.09 50.75 
0.2,0.2,0.2,0.2,0.2 72.72 73.35 70.75 51.05 
0.0125,0.025,0.05,0.1,0.2 39.58 39.20 37.27 32.23 
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Table A3.15 Power(%) calculation for n1=100 and n2=300 (5 doses) 
Effect size of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase 
III Design 
0,0,0,0,0.2 58.57 57.96 54.81 54.89 
0,0,0,0.1,0.2 51.53 51.19 48.41 47.24 
0,0,0,0.2,0.2 73.26 73.08 69.48 65.18 
0,0,0.2,0.2,0.2 78.84 78.95 75.61 68.13 
0,0.2,0.2,0.2,0.2 81.61 81.95 79.01 69.13 
0.2,0.2,0.2,0.2,0.2 83.49 83.97 81.40 69.63 
0.0125,0.025,0.05,0.1,0.2 48.67 48.41 45.77 44.17 
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Table A3.16 Power(%) calculation for n1=100 and n2=400 (5 doses) 
Effect size of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0,0.2 66.34 65.87 62.93 63.7 
0,0,0,0.1,0.2 58.00 57.71 55.21 55.13 
0,0,0,0.2,0.2 81.39 81.25 78.17 75.71 
0,0,0.2,0.2,0.2 86.53 86.63 83.93 79.07 
0,0.2,0.2,0.2,0.2 88.84 89.08 86.78 80.09 
0.2,0.2,0.2,0.2,0.2 90.16 90.49 88.46 80.5 
0.0125,0.025,0.05,0.1,0.2 54.60 54.38 52.05 51.87 
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Table A3.17 Power(%) calculation for n1=100 and n2=500 (5 doses) 
Effect size of the doses 
 
Our 
method 
Inverse 
Normal 
Method 
Fisher’s 
Method 
Traditional Separate 
Phase II and Phase III 
Design 
0,0,0,0,0.2 71.35 71.04 68.53 70.46 
0,0,0,0.1,0.2 61.90 61.72 59.62 60.5 
0,0,0,0.2,0.2 86.51 86.42 83.88 83.95 
0,0,0.2,0.2,0.2 91.26 91.31 89.16 87.23 
0,0.2,0.2,0.2,0.2 93.25 93.40 91.59 88.38 
0.2,0.2,0.2,0.2,0.2 94.28 94.49 92.9 88.83 
0.0125,0.025,0.05,0.1,0.2 58.05 57.91 56.01 56.83 
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